Skip to main content
eLife logoLink to eLife
. 2022 Mar 21;11:e75230. doi: 10.7554/eLife.75230

Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43

Dongeun Heo 1, Jonathan P Ling 1,2, Gian C Molina-Castro 1, Abraham J Langseth 1, Ari Waisman 3, Klaus-Armin Nave 4, Wiebke Möbius 4,5,6, Phil C Wong 2, Dwight E Bergles 1,7,
Editors: Beth Stevens8, Gary L Westbrook9
PMCID: PMC8970587  PMID: 35311646

Abstract

Generation of oligodendrocytes in the adult brain enables both adaptive changes in neural circuits and regeneration of myelin sheaths destroyed by injury, disease, and normal aging. This transformation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes requires processing of distinct mRNAs at different stages of cell maturation. Although mislocalization and aggregation of the RNA-binding protein, TDP-43, occur in both neurons and glia in neurodegenerative diseases, the consequences of TDP-43 loss within different stages of the oligodendrocyte lineage are not well understood. By performing stage-specific genetic inactivation of Tardbp in vivo, we show that oligodendrocyte lineage cells are differentially sensitive to loss of TDP-43. While OPCs depend on TDP-43 for survival, with conditional deletion resulting in cascading cell loss followed by rapid regeneration to restore their density, oligodendrocytes become less sensitive to TDP-43 depletion as they mature. Deletion of TDP-43 early in the maturation process led to eventual oligodendrocyte degeneration, seizures, and premature lethality, while oligodendrocytes that experienced late deletion survived and mice exhibited a normal lifespan. At both stages, TDP-43-deficient oligodendrocytes formed fewer and thinner myelin sheaths and extended new processes that inappropriately wrapped neuronal somata and blood vessels. Transcriptional analysis revealed that in the absence of TDP-43, key proteins involved in oligodendrocyte maturation and myelination were misspliced, leading to aberrant incorporation of cryptic exons. Inducible deletion of TDP-43 from oligodendrocytes in the adult central nervous system (CNS) induced the same progressive morphological changes and mice acquired profound hindlimb weakness, suggesting that loss of TDP-43 function in oligodendrocytes may contribute to neuronal dysfunction in neurodegenerative disease.

Research organism: Mouse

Introduction

The distribution of myelin in the adult brain is not static, as new oligodendrocytes continue to be generated in response to changes in experience, such as enhanced sensory input and intense motor learning (Hughes et al., 2018; Xiao et al., 2016). As a result, oligodendrocyte lineage cells exist in a developmental continuum throughout life, consisting of oligodendrocyte precursor cells (OPCs) that maintain their density through proliferation (Hughes et al., 2013), and cells in the process of maturing from premyelinating to myelinating oligodendrocytes. This ongoing oligodendrogenesis is necessary to prolong the period of circuit maturation (Benamer et al., 2020), enable adaptive changes in myelination (Gibson et al., 2014), and restore myelin lost through aging or demyelinating injuries (Orthmann-Murphy et al., 2020; Bacmeister et al., 2020). The transition from progenitor to myelin-forming oligodendrocyte requires profound transcriptional changes, in which myelin-associated gene networks are activated and mRNAs are transported to distal processes to direct sites of axon ensheathment and membrane compaction (Müller et al., 2013). These transcriptional and post-transcriptional processes are orchestrated by RNA-binding proteins. However, the factors that coordinate key developmental transitions within the oligodendrocyte lineage to enable OPC homeostasis and myelin dynamics are not well understood.

TDP-43 (TAR DNA-binding protein 43 kDa) is a DNA/RNA-binding protein that serves as a master regulator of RNA metabolism, controlling transcriptional integrity, post-transcriptional stability, and localization of mRNAs (Warraich et al., 2010). Within the nucleus, TDP-43 prevents incorporation of cryptic exons into mature mRNA by binding to UG-rich motifs within intronic sequences (Ling et al., 2015). Loss of TDP-43 in neurons results in missplicing of pre-mRNAs, resulting in gain and loss of function alterations in the landscape of expressed proteins that influence their structure, function, and longevity (Ling et al., 2015; Donde et al., 2019; Ma et al., 2021; Brown et al., 2021). In many neurodegenerative diseases, including frontotemporal dementia, Alzheimer’s disease (AD), amyotropic lateral sclerosis (ALS), and multiple sclerosis (MS), cytoplasmic mislocalization and aberrant aggregation of TDP-43 have been observed in affected regions of the CNS (Neumann et al., 2006; Ling et al., 2015; Sun et al., 2017; Masaki et al., 2020; Salapa et al., 2020). Moreover, mutations in TARDBP are responsible for both familial and sporadic forms of ALS (Kapeli et al., 2017; Ince et al., 2011), suggesting that altered mRNA processing by TDP-43 may contribute to cellular pathology and functional impairment in both sporadic and inherited forms of neurodegenerative disease. Although neurons have been the primary focus of research into TDP-43-associated pathologies, nuclear exclusion, and cytoplasmic aggregation of TDP-43 also occur in glial cells in neurodegenerative diseases, such as MS (Neumann et al., 2006; Masaki et al., 2020; Rohan et al., 2014), suggesting that glial cell dysfunction could impair both OPC homeostasis and remyelination. However, much less is known about the role of TDP-43 in mRNA metabolism or the impact of its loss within oligodendroglia at distinct stages of maturation.

Genetic deletion of TDP-43 in mice results in embryonic lethality due to impaired expansion of inner cell mass during early embryogenesis (Sephton et al., 2010), suggesting that it is essential for cell survival. However, selective deletion experiments indicate that the effects of TDP-43 are cell type specific and diverse (Jeong et al., 2017), reflecting differences in transcriptional state. In neurons, conditional inactivation of TDP-43 induces impairment in neuronal function and progressive neurodegeneration (Donde et al., 2019; Iguchi et al., 2013; Yang et al., 2014; Wu et al., 2019). Conditional knockout of Tardbp in microglia enhanced expression of NF-κB and NLRP3, leading to a more activated phenotype characterized by enhanced phagocytosis (Zhao et al., 2015; Paolicelli et al., 2017), while loss of TDP-43 in astrocytes promoted their transition to a reactive A1 phenotype associated with neuronal injury (Peng et al., 2020; Walker et al., 2014). In Schwann cells, genetic deletion of Tardbp did not affect their survival or myelinic potential, but impaired formation and maintenance of paranodal junctions (Chang et al., 2021), while deletion from both newly generated oligodendrocytes and Schwann cells induced necroptosis of oligodendrocytes and early mortality (Wang et al., 2018). These results indicate that TDP-43 regulates transcriptional integrity of different genes based on cellular context, highlighting the need to define TDP-43 functions within different cellular states. As oligodendroglia consist of both proliferating progenitors and cells in distinct states of maturation, their unique transcriptional profiles may render them differentially sensitive to loss of TDP-43.

Here, we used in vivo targeted genetic manipulations of the oligodendrocyte lineage to define the consequences of TDP-43 loss of function in the mouse brain. OPCs were the most vulnerable to this manipulation, as selective deletion of TDP-43 from OPCs resulted in their rapid death, progressing from the corpus callosum to the overlying cortical gray matter. However, this progenitor depletion was transient, as homeostatic proliferation of OPCs that retained TDP-43 expression led to rapid repopulation and restoration of their normal density. Unexpectedly, the consequences of deletion of TDP-43 in oligodendrocytes were dependent on their stage of maturation. Early deletion resulted in the progressive degeneration of mature oligodendrocytes, leading to seizures and premature lethality. In contrast, late deletion largely spared oligodendrocytes, and mice survived without seizures, indicating that TDP-43 may be dispensable within mature oligodendrocytes. Strikingly, both early and late manipulation of TDP-43 in oligodendrocytes led to profound morphological changes, accompanied by thinner and fewer myelin sheaths, as well as progressive, inappropriate wrapping of neuronal somata and blood vessels. Conditional removal of TDP-43 from oligodendrocytes in the adult CNS induced similar morphological changes and was associated with profound hindlimb weakness. Differential transcriptional analysis of oligodendrocytes revealed that loss of TDP-43 led to missplicing of RNAs encoding key genes involved in oligodendrocyte morphogenesis and myelination, changes that may contribute to abnormal neuronal activity and neurodegeneration in diverse neurological diseases.

Results

Selective deletion of TDP-43 from OPCs induces their progressive loss

Oligodendrocytes are derived from an abundant, widely distributed population of lineage restricted progenitors, termed OPCs, that maintain their density through local homeostatic proliferation (Hughes et al., 2013). The dynamic nature of these cells may render them particularly susceptible to environmental and genetic perturbations. To determine how loss of TDP-43 affects OPCs in vivo, we selectively deleted Tardbp from OPCs in young adult Pdgfra-CreER;Tardbpfl/fl;RCE (PDGFRα-TDP43 cKO) mice, by administering tamoxifen at P90 and then collecting brain tissue 2 weeks later (P90 + 14) (Figure 1A). Inclusion of the RCE transgene (Rosa-CAG-LSL-EGFP) allows the visualization of the morphology of Cre-recombined cells (Sousa et al., 2009). Immunolabeling for EGFP and NG2, a proteoglycan highly expressed by OPCs, revealed that this manipulation induced recombination in most OPCs (EGFP+NG2+/NG2+ cells: 94.75 ± 0.75%, n = 4) (Figure 1B), resulting in near complete depletion of OPCs from the corpus callosum, while those in the overlying cortical gray matter were preserved (Figure 1C,E; Figure 1D, panel i) (OPCs/mm3: Corpus callosum 14 dpi, Control = 6910 ± 201; cKO = 987 ± 201, n = 3, p < 0.001, one-way ANOVA with Tukey’s multiple comparisons test). However, when the interval between tamoxifen administration and sacrifice was increased to 30 days (P90 + 30), OPCs in gray matter were also depleted (Figure 1C,E; Figure 1D, panel ii) (OPCs/mm3: Cortex 30 dpi, Control = 5247 ± 236; cKO = 811 ± 187, n = 3, p < 0.001, one-way ANOVA with Tukey’s multiple comparisons test). Remarkably, OPCs in white matter had repopulated by this time, and highly polarized OPCs were visible migrating out of the corpus callosum into the gray matter (Figure 1C, red arrowhead; Figure 1D, panel iii; Figure 1E). When the interval between tamoxifen administration and sacrifice was increased by another 30 days (P90 + 60), OPCs had regained their normal density and tiled distribution throughout gray and white matter (Figure 1C,E). As expected, this repopulation was associated with enhanced proliferation of OPCs, visible by increased Ki-67 immunoreactivity in PDGFRα-TDP43 cKO (Figure 1F; Figure 1—figure supplement 1A). Despite this extensive death of OPCs, there were no signs of astrogliosis, as assessed by glial fibrillary acidic protein (GFAP) immunoreactivity (Figure 1—figure supplement 1B), in accordance with the tolerance to normal turnover of these cells (Hughes et al., 2013). This lack of glial reactivity in response to widespread loss of OPCs was also described in a previous OPC ablation study using diphtheria toxin (Birey et al., 2015), suggesting that OPC death does not induce reactive changes in astrocytes or microglia. Deletion of Tardbp in P180 mice also resulted in a robust loss of OPCs in the corpus callosum within 14 days (P180 + 14) (Figure 1—figure supplement 1C), indicating that the dependence on TDP-43 extends into the adult CNS. Together, these results show that TDP-43 is required for the survival and homeostasis of oligodendrocyte progenitors.

Figure 1. Oligodendrocyte precursor cells (OPCs) require TDP-43 for survival.

(A) Schematics of CreER activation. At P90, tamoxifen was administered for five consecutive days. Tissue samples were collected 14, 30, and 60 days after the last day of tamoxifen injection. (B) Pdgfra-CreER;RCE allows labeling of oligodendrocyte lineage cells. Yellow arrowheads indicate EGFP+NG2+ OPCs whereas blue arrowheads indicate EGFP+NG2− oligodendrocytes. (C) NG2 staining shows that there is a regional progression in OPC degeneration from white matter to gray matter. The dotted line separates the corpus callosum from cortex. i, ii, and iii regions are zoomed in in D. (D) Region i shows the corpus callosum with a near complete loss of OPCs at P90 + 14. ii shows loss of OPCs in the cortex at P90 + 30. iii shows highly polarized OPCs migrating from the corpus callosum up to cortex. (E) Quantification of NG2+ OPC density in corpus callosum and cortex at 14, 30, and 60 days post injection of tamoxifen (dpi). Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test (n = 4, ***p value < 0.001, n.s. p value >0.05). (F) Ki-67+NG2 + proliferating OPCs increase in number at P90 + 60 in the corpus callosum of PDGFRα-TDP43 KO.

Figure 1.

Figure 1—figure supplement 1. PDGFRα-TDP43 cKO shows a regional difference in degeneration of oligodendrocyte precursor cells (OPCs).

Figure 1—figure supplement 1.

(A) Quantification of NG2+Ki-67+ proliferating OPCs in Figure 1F (unpaired, two-tailed Student’s t-test, ***p value = 0.0002, n = 3,2). (B) Coronal brain sections immunostained for GFAP at 30 and 60 days after tamoxifen injection in PDGFRα-TDP43 Control and cKO. (C) Genetic deletion of Tardbp in old, 6-month-old PDGFRα-TDP43 cKO induces OPC degeneration in the corpus callosum at 14 dpi (similar to Figure 1E). (D) Coronal brain sections immunostained for EGFP, NG2, and PDGFRα at 30 days after tamoxifen injection in PDGFRα-TDP43 Control and cKO. Upon Cre recombination, EGFP+NG2+PDGFRα+ OPCs undergo degeneration.

Deletion of TDP-43 from premyelinating oligodendrocytes impairs oligodendrocyte survival

OPCs undergo a profound series of structural and physiological changes as they differentiate into myelinating oligodendrocytes, a transition enabled by activation of distinct gene regulatory networks expressed at different stages of their maturation (Xu et al., 2020; He et al., 2017). To determine if postmitotic oligodendrocytes are similarly dependent on TDP-43, we deleted Tardbp from these cells using two constitutive Cre lines which differ in their timing of expression during oligodendrocyte maturation: MogiCre, which has been used extensively to manipulate mature oligodendrocytes (Buch et al., 2005; Larson et al., 2018; Figure 2—figure supplement 1) and Mobp-iCre, a novel BAC transgenic line that we developed (see Materials and methods) (Figure 2—figure supplement 2). Single-cell RNA-Seq results indicate that Mobp expression is robust at the premyelinating oligodendrocyte stage, whereas expression of Mog does not increase substantially until the myelin-forming stage (Marques et al., 2016; Hrvatin et al., 2018; Figure 2—figure supplement 3). Gene expression analysis of oligodendroglia at these stages revealed that many mRNAs are differentially expressed, including Gadd45a, which participates in DNA methylation, and Opalin (Tmem10) that has been shown to promote oligodendrocyte differentiation (Barreto et al., 2007; de Faria et al., 2019; Figure 2—figure supplement 4), suggesting that the consequences of TDP-43 may be distinct.

Abolishing TDP-43 expression at these different stages resulted in very different outcomes. Mice in which TDP-43 was constitutively removed from premyelinating oligodendrocytes (Mobp-iCre;Tardbpfl/fl;RCE) (Mobp-TDP43 KO) began to exhibit spontaneous seizures at ~P110 (Figure 2B, red arrowhead; Video 1) and 100% died prematurely by P180 (Figure 2B, dark orange line), similar to the phenotype exhibited by CnpCre;Tardbpfl/fl mice (Wang et al., 2018), in which recombination occurs in OPCs, early postmitotic oligodendrocytes, and Schwann cells in the PNS (Lappe-Siefke et al., 2003; Chang et al., 2021; Tognatta et al., 2017). In contrast, mice in which TDP-43 was deleted from mature oligodendrocytes (MogiCre;Tardbpfl/fl;RCE) (Mog-TDP43 KO) did not exhibit spontaneous seizures or other gross behavioral abnormalities and survived as well as controls (Figure 2B, blue lines).

Figure 2. Early deletion of TDP-43 in premyelinating oligodendrocytes leads to seizure development, premature death, and increased oligodendrocyte turnover.

(A) Diagram of oligodendrocyte development showing Mobp-iCre induces Tardbp deletion at the premyelinating oligodendrocyte stage whereas Mog-iCre targets myelinating oligodendrocytes. (B) Kaplan–Meier survival curve for Mobp-TDP43 (orange) and Mog-TDP43 (blue) mouse lines. Dotted line indicates the 95% confidence interval. Log-rank (Mantel–Cox) statistical test showed significance at p value <0.0001 (n = 58, 33, 40, and 32). Red arrowhead points to ~P110 when the animals first exhibit spontaneous seizures. (C) ASPA+ oligodendrocyte staining in the motor cortex of Mobp-TDP43 and MOG-TDP43 mouse lines at P30, P90, and P180. (D) Quantification of ASPA+ oligodendrocyte density shows that there is no statistical difference between the samples at any given timepoint (one-way ANOVA with Tukey’s multiple comparisons test, n = 3, n.s. p value >0.05). (E) Immunostaining for Ki-67 and NG2 to identify proliferating oligodendrocyte precursor cells (OPCs) in Mobp-TDP43 and Mog-TDP43 at P90. (F) Quantification of Ki-67+NG2+ proliferating OPC density shows that it is statistically significantly increased in Mobp-TDP43 KO whereas Mog-TDP43 KO shows a trend toward an increased density (one-way ANOVA with Tukey’s multiple comparisons test, n = 4, ***p value <0.001, n.s. p value = 0.3776).

Figure 2.

Figure 2—figure supplement 1. Quantification of Mog-iCre recombination efficiency.

Figure 2—figure supplement 1.

(A) Maximum intensity z-projection confocal images of the motor cortex from Mog-iCre × RCE mice at P90 and P180 immunostained with GFP and ASPA. (B) Quantification of % recombination (EGFP+ASAP+/ASPA+) and % ASPA+/EGFP+ to show recombination efficiency and specificity in P90 and P180 mouse cortex. n = 3.
Figure 2—figure supplement 2. Characterization of Mobp-iCre and Mobp-iCreERT2 mouse lines.

Figure 2—figure supplement 2.

(A) Schematic of tamoxifen injection in different Mobp-iCreER mouse lines at P35. (B) Representative images of ASPA (oligodendrocyte marker) and NG2 (oligodendrocyte precursor cell [OPC] marker) from Line #10 without tamoxifen and Line #8,16 with and without tamoxifen injections. (C) Quantification of % recombination (EGFP+ASAP+/ASPA+) and % ASPA+/EGFP+ to show recombination efficiency and specificity in Lines #10 and #8,16 in cortex, corpus callosum (CC), spinal cord gray matter (SC GM), and spinal cord white matter (SC WM).
Figure 2—figure supplement 3. Mobp-TDP43 and Mog-TDP43 mouse lines exhibit differences in response to loss of TDP-43.

Figure 2—figure supplement 3.

(A) Mobp and Mog expression in oligodendrocyte lineage cells (adapted from https://greenberg.hms.harvard.edu/gene-database/ Hrvatin et al., 2018). (B) Mobp and Mog expression in the lineage of oligodendrocytes (adapted from http://linnarssonlab.org/oligodendrocytes/ Marques et al., 2016).
Figure 2—figure supplement 4. Differential gene expression between premyelinating (orange) and myelinating (blue) oligodendrocytes (OL) (reproduced from the raw single-cell RNA-Seq dataset in Hrvatin et al., 2018).

Figure 2—figure supplement 4.

Top 16 differentially expressed genes are shown. All genes are statistically significantly differentially expressed (q value <0.01).
Figure 2—figure supplement 5. Mobp-TDP43 KO animals exhibit a higher oligodendrocyte turnover rate and increased astrogliosis.

Figure 2—figure supplement 5.

(A) In situ hybridization for lncOL1 (9630013A20Rik) shows increased number of premyelinating oligodendrocytes in P150 Mobp-TDP43 KO compared to the Control. (B) Immunostaining for GFAP in the motor cortex at P180 in Mobp-TDP43 and Mog-TDP43 mouse lines. Scale bar = 500 μm. (C) Quantification of mean GFAP intensity (arbitrary unit; a.u.) in the motor cortex. One-way ANOVA with Tukey’s multiple comparisons test, ***p value <0.001, n.s. p value >0.05.

Video 1. Video of Mobp-TDP43 Control and KO mice where Mobp-TDP43 KO mice undergo spontaneous seizures and reduced threshold for seizures.

Download video file (25.7MB, mp4)

In contrast to the extensive demyelination and oligodendrocyte necroptosis observed in CnpCre;Tardbpfl/fl mice (Wang et al., 2018), there was no change in the density of ASPA+ mature oligodendrocytes in the motor cortex of Mobp-TDP43 KO or Mog-TDP43 KO mice at P30, P90, or P180 (end stage) (Figure 2C,D). However, degenerating oligodendrocytes can be rapidly replaced through differentiation of OPCs (Kang et al., 2013), obscuring extensive cell loss. As remaining OPCs proliferate to maintain their density, higher rates of OPC proliferation are associated with oligodendrocyte degeneration (Kang et al., 2013). In accordance with the different behavioral phenotypes of the Mobp-TDP43 KO and Mog-TDP43 KO mice, OPCs also exhibited strikingly different behaviors in these animals. Early deletion of TDP-43 in premyelinating oligodendrocytes (Mobp-TDP43 KO) was associated with a dramatic increase in Ki-67+ OPCs at P90 (Figure 2E,F) (Ki-67+ OPCs/mm3: Mobp-TDP43 Control = 71 ± 45; Mobp-TDP43 KO = 941 ± 121, n = 4, p < 0.001, one-way ANOVA with Tukey’s multiple comparisons test), whereas deletion of TDP-43 from mature oligodendrocytes (Mog-TDP43 KO) was not associated with a significant change in OPC proliferation (Figure 2E,F) (Ki-67+ OPCs: Mog-TDP43 Control = 24 ± 24; Mog-TDP43 KO = 212 ± 89, n = 4, p > 0.05, one-way ANOVA with Tukey’s multiple comparisons test). Moreover, there was an increase in the number of newly formed oligodendrocytes in Mobp-TDP43 KO, as assessed by the emergence of cells that expressed lncOL1 (Figure 2—figure supplement 4A), a long noncoding RNA that is transiently expressed in premyelinating oligodendrocytes (He et al., 2017), suggesting that there is an increased turnover of oligodendrocytes. Astrogliosis (visible through the increase in GFAP immunoreactivity) was also prominent in Mobp-TDP43 KO mice (Figure 2—figure supplement 4B, C), further supporting the conclusion that early deletion of TDP-43 leads to degeneration and subsequent regeneration of oligodendrocytes. Together, these results indicate that there is a critical period for TDP-43 function during oligodendrocyte maturation, with deletion at an early stage leading to progressive oligodendrocyte degeneration, seizures, and premature death, consequences that are avoided when oligodendrocytes mature beyond this stage.

TDP-43 loss in oligodendrocytes results in thinner myelin, fewer myelinated axons, and aberrant nodes of Ranvier

In both Mobp-TDP43 KO and Mog-TDP43 KO mice, oligodendrocytes were able to mature and form myelin sheaths, global myelin tracts within the brain were established (Figure 3—figure supplement 1A), and there was no evidence of astrogliosis early in development (P30) (Figure 3—figure supplement 2). To determine if oligodendrocytes in these mice were capable of forming normal myelin at the ultrastructural level, we performed transmission electron microscopy (TEM) of the corpus callosum (Figure 3—figure supplement 1A, red boxes). Myelinated axons in Mobp-TDP43 KO and Mog-TDP43 KO mice had significantly higher G ratios than controls at both P90 and P180, with thinner sheaths formed (Figure 3A–D). Although axons with diameters less than 0.6 µm were not as severely affected at P90, their myelin was also markedly thinner in P140–180 mice (Figure 3—figure supplement 1B). In addition to thinner myelin sheaths, the number of myelinated axons was also reduced in both oligodendrocyte TDP-43 knockouts (Figure 3E,F). Morphological reconstructions of individual oligodendrocytes and their associated myelin sheaths revealed that Mog-TDP43 KO oligodendrocytes tended to exhibit less myelin basic protein (MBP) immunoreactivity per process (revealed by EGFP labeling), indicative of decreased myelin production (Figure 3—figure supplement 3). These results indicate that despite achieving a mature myelinating stage, the total myelin output of TDP-43-deficient oligodendrocytes is ultimately lower (summarized in Figure 3—figure supplement 4).

Figure 3. Loss of TDP-43 oligodendrocytes leads to fewer and thinner myelin sheaths.

(A) Representative transmission electron micrographs of individual axon cross-sections from Mobp-TDP43 and Mog-TDP43 mouse lines at P90 show decreased myelin sheath thickness (yellow) in the KO. Scale bar = 250 nm. (B) G ratios of individual myelinated axons as a function of axon caliber (μm) in the corpus callosum of Mobp-TDP43 (orange) and Mog-TDP43 (blue) mouse lines at P90. n = 3–4/genotype. The solid lines show the lines of best fit with a linear function. (C) A for P140–180 timepoint. (D) B for P140–180 timepoint. (E) Representative electron micrographs of Mobp-TDP43 and Mog-TDP43 mouse lines at P90 and P140–180 show a decreased density of myelinated axons in the KO. Scale bar = 1 μm. (F) Quantification of myelinated axon density in Mobp-TDP43 (orange) and Mog-TDP43 (blue) mouse lines at P90 and P140–180. Statistical significance was determined using unpaired, two-tailed Student’s t-test (**p value <0.01, *p value <0.05, n.s. p value >0.05).

Figure 3.

Figure 3—figure supplement 1. Both Mobp-TDP43 KO and Mog-TDP43 KO brains show significantly increased g-ratio and aberrant myelination.

Figure 3—figure supplement 1.

(A) Tiled mouse brain coronal sections from P90 Mobp-TDP43 and Mog-TDP43 mouse lines immunostained with myelin basic protein (MBP). Red box indicates where transmission electron microscopy (TEM) was performed. (B) Bar graphs of G ratio values for individual axons in different bins of axon caliber (μm). Statistical significance was determined using unpaired, two-tailed Student’s t-test (***p value <0.001, **p value <0.01, n.s. p value >0.05). (C) Examples of abnormal myelination from TEM at the ultrastructural level. Scale bar = 250 nm. Yellow arrowheads indicate abnormal myelin structures.
Figure 3—figure supplement 2. Immunostaining for GFP, GFAP, and myelin basic protein (MBP) at P30 in Mobp-TDP43 and Mog-TDP43 mouse lines shows that oligodendrocytes and myelin are formed without astrogliosis.

Figure 3—figure supplement 2.

Figure 3—figure supplement 3. Morphological reconstruction of individual oligodendrocytes and their myelin sheaths.

Figure 3—figure supplement 3.

(A) Representative images of individually traced oligodendrocytes (EGFP) and myelin sheaths (myelin basic protein, MBP) from motor cortex of P180 Mog-TDP43 Control and KO. (B) Quantification of the overlap between EGFP+ oligodendrocyte processes and MBP + myelin shows a trend toward a decrease in the overlap for Mog-TDP43 KO oligodendrocytes compared to the Control oligodendrocytes (Control: 0.9718 ± 0.007, KO: 0.9017 ± 0.036, n = 3, p value = 0.1252).
Figure 3—figure supplement 4. Diagram of Control (green) and KO (red) oligodendrocytes, where KO oligodendrocytes are making fewer and thinner myelin sheaths.

Figure 3—figure supplement 4.

Figure 3—figure supplement 5. TDP-43 loss in oligodendrocytes leads to abnormal nodal structures.

Figure 3—figure supplement 5.

(A) Examples of normal (yellow arrowheads) and abnormal (red arrowheads) nodal and paranodal proteins (Caspr, βIV-spectrin, and myelin basic protein [MBP]) in Control and KO at P90. (B) Diagram of double myelination by a KO oligodendrocyte (red) causing Caspr triads (cyan) at the node of Ranvier (magenta).

In peripheral nerves, loss of TDP-43 from Schwann cells results in complete loss of paranodal junctions and a 50% decrease in conduction velocity (Chang et al., 2021). Immunocytochemical analysis revealed that TDP-43-null oligodendrocytes also frequently exhibited abnormal nodes of Ranvier (NOR). While normal NOR exhibit focal localization of βIV spectrin at the node flanked by Caspr within the paranodes (Figure 3—figure supplement 3A, yellow arrowheads), in mice with TDP-43 KO oligodendrocytes, nodes often consisted of Caspr triads and βIV-spectrin doublets (Figure 3—figure supplement 5A, red arrowheads). EM analysis revealed that some axons exhibited double myelination (Figure 3—figure supplement 1C), which may contribute to these macroscopic changes in organization of node-associated proteins (Figure 3—figure supplement 5B), as well as unusual accumulation of mitochondria and vacuoles in the inner tongue.

Oligodendrocytes without TDP-43 undergo profound morphological changes

To define the progressive structural changes exhibited by TDP-43-deficient oligodendrocytes, we examined their morphologies in Mobp-TDP43 KO and Mog-TDP43 KO mice using EGFP (expressed from the conditional RCE transgene) (Sousa et al., 2009). Histological analysis of motor cortex in these mice revealed that oligodendrocyte density gradually increased from P30 to P180 in both control and mutant (KO) mice (Figure 2D); however, while EGFP was largely restricted to oligodendrocyte somata in controls, due to the limited cytoplasm in myelin sheaths, mice with TDP-43-deficient oligodendrocytes exhibited a dramatic increase in EGFP fluorescence in the surrounding parenchyma at P90 and P180 (Figure 4—figure supplement 1). This morphological change in oligodendrocytes was observed throughout the brain, as well as the optic nerve and spinal cord (Figure 4—figure supplement 2), suggesting that this phenotype is fully penetrant in the CNS. Repetitive in vivo two photon imaging of individual oligodendrocytes in the motor cortex of Mobp-TDP43-RCE KO mice over 2 weeks revealed that these aberrant structures are highly dynamic (Figure 4—figure supplement 3; Video 2), indicating that these normally highly stable cells exhibit enhanced growth when TDP-43 is absent. High-resolution imaging revealed that much of this additional EGFP fluorescence arose from thick cytoplasmic processes of oligodendrocytes that often ended in circular or cuff-like structures (Figure 4A,B). Immunostaining for NeuN revealed that circular structures arose from inappropriate wrapping of neuronal cell bodies (Figure 4C,D; Video 3). These abnormal associations were not rare events and were visible in single coronal brain sections immunostained for NeuN and EGFP (Figure 4—figure supplement 4).

Figure 4. Oligodendrocytes without TDP-43 undergo aberrant morphological changes and exhibit aberrant wrapping of nonaxonal structures.

(A) Representative images of single oligodendrocytes from Control (Mobp-EGFP) and Mobp-TDP43 KO at P180. Scale bar = 25 μm. (B) Examples of abnormal structures formed by TDP-43 KO oligodendrocytes. Yellow arrowheads point to abnormal structures for each category. Scale bar = 10 μm. (C) Immunostaining of GFP and NeuN in Mobp-TDP43-RCE KO shows a formation of basket-like EGFP+ structure that ensheaths NeuN+ neuronal cell body (yellow arrowhead). Blue arrowhead points to a tubing-like EGFP+ structure. Scale bar = 25 μm. (D) Optical serial sections representing 1.5 μm increments in the z-axis showing wrapping of a NeuN+ neuronal soma by EGFP+ oligodendrocyte processes in Mobp-TDP43-RCE KO at P180. Scale bar = 10 μm. (E) Immunostaining of GFP and GS-Isolectin in Mog-TDP43-RCE KO at P180 shows tight wrapping of the blood vessels by EGFP+ oligodendrocyte processes (blue arrowheads). Scale bar = 50 μm. (F) In vivo imaging of Mobp-TDP43-RCE KO mouse after retro-orbital injection of 70 kDa dextran–rhodamine shows wrapping of the capillaries by EGFP+TDP-43 KO oligodendrocyte. Blue arrows show sites of wrapping. Scale bar = 25 μm.

Figure 4.

Figure 4—figure supplement 1. Oligodendrocytes undergo progressive morphological changes with loss of TDP-43.

Figure 4—figure supplement 1.

EGFP images from the motor cortex of Mobp-TDP43-RCE and Mog-TDP43-RCE mouse lines at P30, P90, and P180 show progressive changes in EGFP+ oligodendrocyte morphology where there is no difference at P30 and dramatic abnormality by P180 (yellow arrowheads). Scale bar = 50 μm.
Figure 4—figure supplement 2. Abnormal oligodendrocyte morphological phenotype due to loss of TDP-43 is persistent throughout the CNS.

Figure 4—figure supplement 2.

(A) Tiled coronal mouse brain section to show that hypertrophic oligodendrocyte changes can be seen throughout the brain at P180. (B) EGFP immunoreactivity shows that abnormal oligodendrocyte morphologies can be seen in the optic nerve and spinal cord.
Figure 4—figure supplement 3. Longitudinal two-photon in vivo imaging of Mobp-TDP43 KO oligodendrocytes across 14 days.

Figure 4—figure supplement 3.

Figure 4—figure supplement 4. Aberrant wrapping of non-axonal structures is prevalent in Mobp-TDP43 KO brains.

Figure 4—figure supplement 4.

(A) Motor cortex of P180 Mobp-TDP43 KO shows that aberrant EGFP structures can be readily identified. Blue arrowheads indicate tubing-like structures that resemble blood vessel wrapping and yellow arrowheads indicate neuronal wrapping. (B) Quantification of the number of abnormal wrapping of blood vessels (blue) and neuronal soma (yellow) in a given field of view (FOV, 450 × 450 × 35 µm).
Figure 4—figure supplement 5. Loss of TDP-43 in oligodendrocytes potentially contributes to the disruption of blood-brain barrier (BBB) and de-differentiation of oligodendrocytes.

Figure 4—figure supplement 5.

(A) Immunostaining for aquaporin four shows that EGFP+ wrapping displaces aquaporin 4 + astrocyte endfeet (yellow arrowheads). (B) Ki-67+NG2− oligodendrocytes can be found in P180 Mobp-TDP43 KO.

Video 2. Longitudinal in vivo imaging of Mobp-TDP43 KO oligodendrocytes.

Download video file (383.7KB, mp4)

Video 3. 3D video of EGFP+ KO oligodendrocyte that wrap around NeuN+ neuronal somata.

Download video file (5.8MB, mp4)

As the cuff-like structures are reminiscent of astrocyte endfeet (Gundersen et al., 2014), we labeled blood vessels with GS-Isolectin, revealing that EGFP+ oligodendrocyte processes also colocalized with these tubular structures (Figure 4E). To determine if these structures were capillaries, we used in vivo two photon imaging in living Mobp-TDP43-RCE KO mice to visualize both oligodendrocyte processes and capillaries after a retro-orbital injection of dextran–rhodamine. With 4D imaging, it was possible to follow the cytoplasmic processes from individual oligodendrocytes, revealing that they extended unbranched processes to ensheath rhodamine-labeled capillaries (Figure 4F). Histological analysis revealed that regions of capillaries surrounded by oligodendrocyte cuffs exhibited reduced aquaporin four immunoreactivity (Figure 4—figure supplement 5A), a protein restricted to astrocyte endfeet (Gundersen et al., 2014), suggesting that these oligodendrocyte wraps may displace or alter the physiology of astrocytes at capillaries. Remarkably, we also found that some TDP-43 KO oligodendrocytes exhibited immunoreactivity to Ki-67 (Figure 4—figure supplement 5B), suggesting that these cells are reverting to a less mature phenotype. Together, these results indicate that TDP-43 is required maintain the structure of oligodendrocytes and myelin throughout the CNS.

Conditional deletion of TDP-43 from oligodendrocytes in the adult CNS induces abnormal morphological changes and motor discoordination

The results above indicate that constitutive deletion of TDP-43 from myelinating oligodendrocytes induces a profound morphological transformation, and when removed early in their maturation, results in oligodendrocyte degeneration, seizures, and death. Although oligodendrocytes continue to be generated in the adult CNS, most oligodendrocytes are produced in the first two postnatal months (Bergles and Richardson, 2015), indicating that these changes primarily manifest in developing tissue. To determine if loss of TDP-43 function in oligodendrocytes in the mature brain evokes comparable changes, we generated Mobp-iCreER mice, which allow selective Cre-dependent recombination in oligodendrocytes in the adult CNS (see Materials and methods; Figure 2—figure supplement 2). When tamoxifen was administered to P90 Mobp-iCreER;Tardbpfl/fl;RCE mice and analyzed 30 days later (P90 + 30), ASPA+ oligodendrocytes were present in the motor cortex with morphologies comparable to controls (Mobp-iCreER;Tardbp+/+, fl/+) (Figure 5A,B). However, when TDP-43 mutant mice were analyzed 90 days later (P90 + 90), the majority of oligodendrocytes exhibited hypertrophy, as well as cytoplasmic ensheathment of neuronal cell bodies and capillaries (Figure 5B, yellow arrowhead), indicating that TDP-43 is also required to maintain oligodendrocyte structure in the adult CNS. However, the behavioral consequences of TDP-43 deletion in the mature CNS were distinct, as these mice exhibited progressive motor problems, including limp tails, hindlimb clasping (Figure 5C, Video 4), and hindlimb weakness (Figure 5D), but not seizures or premature lethality. We utilized the clinical scoring method established for experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, and found that Mobp-TDP43 cKO developed significant motor weakness within 90 days after Cre recombination (Figure 5E). Although this transformation of oligodendrocytes did not lead to degeneration of motor neurons (Figure 5—figure supplement 1), the spinal cord exhibited enhanced GFAP immunoreactivity (Figure 5F,G), indicative of widespread inflammation, which has been shown to impair motor function without loss of spinal motor neurons (Wang et al., 2018). Thus, adult-onset loss of TDP-43 function in oligodendrocytes, which may occur in disease and injury states (Wiesner et al., 2018; Sun et al., 2017), triggers phenotypes commonly observed in mouse models of ALS, Parkinson’s disease (PD), and MS (Wong and Martin, 2010; Lieu et al., 2013; Gharagozloo et al., 2021).

Figure 5. Adult loss of TDP-43 in oligodendrocytes leads to hindlimb weakness.

(A) Mobp-iCreER allows Tardbp deletion at mature oligodendrocytes in the adult CNS. Schematics of CreER activation where tamoxifen is administered for five consecutive days at P90. Samples are collected for analyses 30 and 90 days after the last day of tamoxifen injection. (B) EGFP images from Mobp-TDP43-RCE Control and cKO at 30 and 90 days after Tardbp deletion. Yellow arrowhead indicates abnormal morphological changes in cKO oligodendrocytes at P90 +90. Scale bar = 25 μm. (C) Examples of limp tail and hindlimb clasping (yellow arrowheads) in Mobp-TDP43 cKO at P90 + 90 from Video 4. (D) Mobp-TDP43 cKO mice develop hindlimb paralysis at P90 + 90 (yellow arrowhead). (E) Experimental autoimmune encephalomyelitis (EAE) clinical score for Control and Mobp-TDP43 cKO mice. All Control mice at P90 + 90 exhibit no obvious changes in motor function whereas Mobp-TDP43 cKO mice develop limp tail and hindlimb weakness, which yield clinical scores between 2 and 2.5 (unpaired, two-tailed Student’s t-test, ***p value = 0.0002, n = 3). (F) Immunostaining for GFP and GFAP in the lumbar spinal cords of Mobp-TDP43-RCE Control and cKO at P90 + 90 shows global astrogliosis indicated by increased immunoreactivity of GFAP. Scale bar = 100 μm. (G) Quantification of mean GFAP fluorescence intensity (arbitrary unit; a.u.) shows a statistically significant increase in the mean intensity of GFAP in the spinal cord of Mobp-TDP43 cKO (unpaired, two-tailed Student’s t-test, **p value = 0.0096, n = 3).

Figure 5.

Figure 5—figure supplement 1. Loss of TDP-43 in oligodendrocytes does not result in degeneration of spinal motor neurons.

Figure 5—figure supplement 1.

(A) ChAT immunostaining in the spinal cord to visualize motor neurons in the ventral spinal cord. (B) Quantification of the number of ChAT+ motor neurons per 35 μm section of the spinal cord (unpaired, two-tailed Student’s t-test, n = 3).

Video 4. Video of Mobp-TDP43 Control and cKO mice where Mobp-TDP43 cKO mice exhibit hindlimb paralysis, limp tail, and hindlimb clasping.

Download video file (13.1MB, mp4)

TDP-43 regulates splicing and represses cryptic exon incorporation in oligodendrocytes

TDP-43 is a highly conserved, multifunctional protein that regulates key aspects of RNA processing. Previous studies have shown that loss of nuclear TDP-43 function, through genetic deletion or disease-induced mislocalization, is sufficient to cause aberrant incorporation of intronic sequences (cryptic exons) into mature mRNA that can alter protein expression and function (Ling et al., 2015; Sun et al., 2017; Donde et al., 2019). Due to the unique complement of RNAs present in different cell types and differences in intron–exon boundaries between organisms, these changes are both cell type and species specific (Jeong et al., 2017). To define the molecular consequences of TDP-43 loss of function in oligodendrocytes, we used fluorescence-activated cell sorting (FACS) to selectively isolate oligodendrocytes from the cortex of P30 Mobp-TDP43-RCE KO and Mog-TDP43-RCE KO mice (and controls) prior to the onset of phenotypic changes (Figure 4A; Figure 3—figure supplement 1), and performed bulk mRNA sequencing (RNA-Seq) to determine gene expression changes (Figure 6A). In both mouse lines, hundreds of genes were differentially expressed, comprising 3–6% of the mouse genome (Figure 6B; Figure 6—figure supplement 1), consistent with the magnitude of changes observed in other cell types and the high incidence of UG repeats recognized by TDP-43 in the genome (Humphrey et al., 2017). The differential gene expression profiles and gene ontology analysis were also distinct between the mutant mouse lines (Figure 6B; Figure 6—figure supplement 2), with early deletion resulting in changes in mRNA processing and cell localization, and latter deletion resulting in changes in regulation of gene expression and metabolic processes.

Figure 6. TDP-43 maintains oligodendrocyte transcriptional integrity by suppressing cryptic exon incorporation in key oligodendrocyte genes.

(A) Bulk RNA-Seq was performed with fluorescence-activated cell sorting (FACS)-isolated EGFP+ oligodendrocytes from P30 Mobp-TDP43-RCE and Mog-TDP43-RCE cortices. (B) Volcano plots comparing KO to Control in Mobp-TDP43 and Mog-TDP43 mouse lines showing statistically significantly differentially expressed genes (fold change >1, adjusted p value [false discovery rate, FDR] <0.05). Blue dots indicate downregulated genes whereas red dots indicate upregulated genes with TDP-43 KO. (C) Visualization of the cryptic exon located in Ermn. Gene annotation is shown on the bottom, labeling exons (thick) and introns (thin). Bulk RNA-Seq reads from Control and KO oligodendrocytes from both Mobp-TDP43 and Mog-TDP43 mouse lines are aligned to the mm10 genome. The cryptic exon in the intron 2 of Ermn is magnified to highlight the difference. (D) Reverse transcription-polymerase chain reaction (RT-PCR) validation of cryptic exon incorporation in Ermn in mouse whole brain tissue from Mog-TDP43 Control and KO. Three primers were used to identify (1) normal transcript (226 bp), (2) cryptic exon incorporated transcript (286 bp), and (3) the presence of cryptic exon (147 bp). Only the KO samples showed bands at 147 and 286 bp that represent cryptic exon incorporation into Ermn mRNA. (E) Western blotting assay to quantify the amount of Ermin protein in Mog-TDP43 Control and KO brains shows that Mog-TDP43 KO brains have a significantly decreased amount of Ermin protein (unpaired, two-tailed Student’s t-test, *p value = 0.0119, n = 4 and 3). (F) Table of genes that are misspliced in oligodendrocytes with loss of TDP-43. Cassette indicates incorporation of a nonconserved, novel cryptic exon whereas alternative splicing means usage of alternative, conserved exons. Exon extension indicates that the intronic sequence following an exon was incorporated into mature mRNA and became part of the exonic sequence.

Figure 6—source data 1. Raw, cropped, and annotated images of the western blot of mouse-Ermin (red; IRDye 680RD) and rabbit-GAPDH (green; IRDye 800CW).
The molecular weight of Ermin is 42 kDa and of GAPDH is 37 kDa.

Figure 6.

Figure 6—figure supplement 1. The number of genes that are statistically significantly differentially expressed between different genotypes (false discovery rate FDR <0.05).

Figure 6—figure supplement 1.

Figure 6—figure supplement 2. Gene ontology (GO) analysis from differentially expressed genes shows that Mobp-TDP43 KO and Mog-TDP43 KO show differential enrichment of biological processes.

Figure 6—figure supplement 2.

Figure 6—figure supplement 3. Immunostaining for Ermin shows that KO oligodendrocytes have reduced cell body expression of Ermin protein compared to the Control.

Figure 6—figure supplement 3.

Figure 6—figure supplement 4. Fragments per kilobase of exon per million mapped fragments (FPKM) of Gpr37, Mag, Gamt, and Opalin in Mobp-TDP43 Control and Mog-TDP43 Control from bulk RNA-Seq in Figure 6.

Figure 6—figure supplement 4.

Unpaired, two-tailed Student’s t-test was used to determine statistical significance at p value <0.05.
Figure 6—figure supplement 5. Summary diagram of how TDP-43 exerts a stage-specific role in oligodendrocyte lineage cells.

Figure 6—figure supplement 5.

Red indicates the degree of effect with the genetic loss of TDP-43. Gray bars indicate the outcomes not addressed and quantified in the conditional deletion of TDP-43 in adult oligodendrocytes.

Analysis of the top 1% of the highest expressed genes enriched in oligodendrocytes, many of which are involved in oligodendrocyte development and myelination, revealed that cryptic exons were often incorporated in their mRNAs (Figure 6F). These included Ermn (Ermin), an oligodendrocyte-specific cytoskeletal protein that regulates process branching and sheath extension (Brockschnieder et al., 2006). TDP-43 loss resulted in the emergence of a novel cryptic exon in intron 2 of the Ermn transcript (Figure 6C). RT-PCR validation using whole mouse brain indicated that this aberrant splicing generated novel splice isoforms, arising from cryptic exon incorporation, exon extension, and truncation (Figure 6D) that may lead to both gain and loss of function. Total Ermin protein was significantly lower in Mobp-TDP43-RCE KO brains compared to controls (Figure 6E), and immunohistochemical staining revealed that Ermin was no longer detected in oligodendrocyte somata in these animals (Figure 6—figure supplement 3). Thus, TDP-43 deficiency leads to an early missplicing of Ermn mRNA, resulting in a partial loss of functional protein. These results indicate that progressive loss of TDP-43 from oligodendrocytes in the adult CNS leads to altered splicing of key regulators of oligodendrocyte growth and morphogenesis, disrupting myelin patterns, inducing gliosis and impairing neuronal function.

Discussion

New oligodendrocytes are generated in the adult CNS to modify circuits and restore myelin lost through injury or disease (Gibson et al., 2014; Orthmann-Murphy et al., 2020). This oligodendrogenesis requires transformation of highly dynamic, proliferative progenitors into stable, postmitotic oligodendrocytes that exhibit extraordinary longevity (Tripathi et al., 2017). The profound structural and functional changes experienced by oligodendrocyte lineage cells are orchestrated by a family of RNA-binding proteins that ensure transcripts are spliced correctly and delivered to their appropriate location within the cell prior to translation (Müller et al., 2013). Cellular stress or direct mutation of these genes can lead to mislocalization and progressive loss of their function, contributing to cellular pathology in diverse neurodegenerative diseases (Kapeli et al., 2017; Purice and Taylor, 2018), but the consequences of these effects within oligodendroglia are not well understood. As oligodendrocyte lineage cells continue to exist in a dynamic developmental continuum in the adult CNS, these changes may influence progenitor homeostasis, lineage progression, cellular survival, and function, depending on the stage at which gene function is disrupted.

To genetically interrogate the role of TDP-43 within different stages of oligodendrocyte maturation, we employed four different Cre and CreER mouse lines: (1) Pdgfra-CreER, (2) Mobp-iCre, (3) MogiCre, and (4) Mobp-iCreER, allowing Tardbp inactivation at discrete stages within the oligodendrocyte lineage in both the developing and mature CNS. Bulk RNA-Seq of purified oligodendrocytes from Mobp-iCre and MogiCre mouse lines showed that this approach was able to target different stages of oligodendrocyte development. In particular, oligodendrocytes labeled by Mobp-iCre showed higher expression of genes enriched in newly formed oligodendrocytes, such as Gpr37 and Mag, whereas those labeled by MogiCre had higher expression of genes enriched in myelin-forming and mature oligodendrocytes, such as Gamt and Opalin (Figure 6—figure supplement 4). Therefore, these two mouse lines, in combination with Pdgfra-CreER mice to manipulate OPCs (Kang et al., 2010), allowed specific interrogation of TDP-43 function at distinct developmental stages, revealing a differential requirement for TDP-43 in cell survival and structural maintenance as OPCs transform into myelinating oligodendrocytes (Figure 6—figure supplement 5).

Homeostasis promotes rapid recovery after OPC depletion

Inducible genetic deletion of Tardbp within OPCs resulted in their rapid degeneration, with loss first detected in the white matter of the corpus callosum 2 weeks after tamoxifen exposure, followed closely by OPC depletion in cortical gray matter, demonstrating that these progenitors require TDP-43 for survival. OPCs represent the largest population of actively dividing cells in the brain outside the subventricular and subgranular germinal zones (Dawson et al., 2003), and maintain a constant density through homeostatic proliferation, in which neighboring cells are induced to divide to replace cells lost through death or differentiation (Hughes et al., 2013). Proliferative cells in many tissues are particularly vulnerable to perturbations in RNA processing, as they undergo metabolic reprogramming requiring extensive transcriptional reorganization (Petasny et al., 2021). Thus, death of only a few proliferating OPCs upon removal of TDP-43 is likely to induce a cascading cellular depletion, in which neighboring cells (also TDP-43 deficient) are induced to proliferate but then die, inducing further proliferation of remaining cells and continuing until the entire population of TDP-43-deficient OPCs is depleted. The higher basal rate of OPC proliferation in white matter, reflecting their higher rate of differentiation (Baracskay et al., 2002; Viganò et al., 2013), may be responsible for more rapid loss of OPCs in this region.

Despite decimation of OPCs after TDP-43 deletion, they were restored to their original density in both gray and white matter within 30 days. Because Tardbp was not inactivated in all OPCs (the proportion limited by the efficiency of tamoxifen-induced recombination), surviving cells that retain TDP-43 are expected to proliferate to reconstitute the population. Consistent with this hypothesis, all OPCs after 30 days of recovery were EGFP negative (Figure 1—figure supplement 1D), indicating that they did not experience Cre activity. These results imply that focal loss of OPCs arising from deficits in TDP-43 should not lead to persistent depletion. It is also possible that the regenerated OPCs were derived from the neural progenitor pool in the subventricular zone, as previously described in the context of remyelination (Xing et al., 2014). Indeed, OPCs have been shown to be exceptionally resistant to perturbations in their distribution and density (Xing et al., 2021; Dang et al., 2019), and rapidly restore their numbers after mass differentiation following demyelination in mice (Baxi et al., 2017; Penderis et al., 2003). Nevertheless, reductions in OPC density have been observed in some human MS lesions (Chang et al., 2000), suggesting that other environmental changes, such as persistent inflammation or gliosis, which may induce TDP-43 mislocalization, may impede their homeostasis and impair their ability to detect demyelinated axons and generate new oligodendrocytes.

Stage-dependent oligodendrocyte survival in the absence of TDP-43

The differentiation of OPCs into mature, myelinating oligodendrocytes is associated with dramatic structural and functional changes, in which highly motile OPCs stabilize, elaborate processes, and select targets for myelination (Kirby et al., 2006; Almeida et al., 2011). Previous studies of Tardbp inactivation using CnpCre mice (Wang et al., 2018; Chang et al., 2021), which recombines in the late progenitor and early premyelinating stages, indicate that loss of TDP-43 during this transition period leads to RIPK1-mediated necroptosis of oligodendrocytes (Wang et al., 2018). We used two constitutive Cre lines (Mobp-iCre and MogiCre) expressed at different stages (early and late) of the maturation of postmitotic oligodendrocytes to determine whether the effects of TDP-43 loss depend on their state of differentiation. In contrast to TDP-43-deficient OPCs, oligodendrocytes were generated, and myelin sheaths were formed in both lines despite inactivation of Tardbp. As the half-life of TDP-43 in vitro was measured to be 12–34 hr (Ling et al., 2010; Lee et al., 2011), it is possible that sufficient residual TDP-43 RNA/protein remains from the OPC stage to enable these initial transitions. Although oligodendrocytes and myelin were generated, TDP-43-deficient oligodendrocytes formed sheaths with fewer wraps and overall fewer axons were myelinated, similar to that observed after CnpCre-mediated deletion (Wang et al., 2018). Reconstructions of individual oligodendrocytes at this stage revealed that fewer sheaths were formed per cell on average, indicating that the overall myelin output of these newly formed oligodendrocytes is compromised in the absence of TDP-43. However, the ultimate outcome of these manipulations was distinct, with early deletion (using Mobp-iCre) resulting in oligodendrocyte degeneration, seizures, and premature death by 6 months of age. This phenotype is similar to, but not as severe as that observed in CnpCre;Tardbpfl/fl mice, in which mature oligodendrocytes, OPCs, premyelinating oligodendrocytes, and Schwann cells were genetically manipulated (Wang et al., 2018; Chang et al., 2021), indicating that disruption of oligodendrocyte TDP-43 levels is sufficient to enhance neuronal excitability and induce premature death.

Although oligodendrocyte density remained stable after Mobp-iCre-mediated Tardbp inactivation, reactive gliosis occurred throughout the CNS and there was an increase in premyelinating oligodendrocytes (lncOL1+) and enhanced proliferation of OPCs, indicative of oligodendrocyte degeneration, similar to the phenotypic changes observed after inducible deletion of oligodendrocytes in the adult CNS (Traka et al., 2015; Oluich et al., 2012). Previous studies have shown that subtler manipulations of mature oligodendrocytes, such as reduction in expression of the inwardly rectifying potassium channel Kir4.1 (Larson et al., 2018) or deletion of the lactate transporter MCT1 (Philips et al., 2021), is sufficient to alter neuronal excitability, highlighting possible functional consequences of TDP-43 loss from these myelinating cells.

Unexpectedly, inactivation of Tardbp from oligodendrocytes at a later developmental stage (with MogiCre) led to a strikingly different outcome: oligodendrocytes survived, OPC proliferation was not enhanced and there was no gliosis. Correspondingly, these animals also did not exhibit seizures or premature death. Bulk RNA-Seq transcriptional analysis of oligodendrocytes with early and late deletion, even prior to the phenotypic changes in Mobp-iCre mice (P30), revealed that pathways involved in gene expression, cellular localization, cell adhesion, and metabolism were affected. Further, differential gene expression analysis of early, premyelinating and myelinating oligodendrocytes from obtained through single-cell RNA sequencing (Hrvatin et al., 2018) revealed that different transcription factors, such as Mycl, and transporters, such as MCT1 (Slc16a1), change in gene expression as oligodendrocytes mature (Figure 2—figure supplement 4). Thus, rapid changes in transcriptional activity during cellular maturation can profoundly alter the impact of TDP-43 depletion, with deficits occurring earlier in maturation leading to more severe outcomes.

The phenotypes observed in response to deletion of TDP-43 from newly generated oligodendrocytes, including subsequent seizures and premature death, may also reflect developmental changes in neural circuits, as this manipulation inactivated Tardbp during a critical phase of brain maturation. Indeed, deletion of TDP-43 from oligodendrocytes in the adult CNS (using Mobp-iCreER) led to distinct pathological changes, such as hindlimb weakness, hindlimb clasping, and limp tail, phenotypes not observed with developmental Tardbp inactivation, and these mice did not exhibit seizures or premature death. Although these distinct phenotypes may arise from differences in the proportion of oligodendrocytes affected, they mirror functional differences observed in neurodevelopmental and neurodegenerative diseases. In neurodevelopmental disorders, such as autism spectrum disorders and schizophrenia, abnormal myelination and altered density of oligodendrocytes have been correlated with neural hyperexcitability and circuit dysfunction (Phan et al., 2020; Fields, 2008). In contrast, oligodendrocyte turnover and demyelination in the adult CNS have been shown to be accompanied by inflammation and neuronal death in neurodegenerative diseases, such as ALS and AD (Kang et al., 2013; Desai et al., 2010; Behrendt et al., 2013). These results suggest that the consequences of TDP-43 loss within the oligodendrocyte lineage depends not only on their stage of maturation, but also the environment in which it occurs, with progressive loss in the adult CNS sufficient to impair motor coordination, a hallmark of neurodegenerative diseases such as ALS.

Aberrant target ensheathment in the absence of TDP-43

In vitro studies indicate that oligodendrocytes have an intrinsic ability to wrap structures of appropriate caliber (>0.4 µm), including inert nanofibers and fixed axons (Rosenberg et al., 2008; Mei et al., 2013; Lee et al., 2012). However, oligodendrocytes in vivo exhibit exquisite target specificity, forming myelin exclusively around axons of appropriate diameter, while avoiding similarly sized dendrites and other nonneuronal structures, such as glial cell processes and capillaries. Moreover, after an initial period of remodeling, the array of myelin sheaths formed by each oligodendrocyte is extremely stable, in terms of position and length along axons. Deletion of TDP-43 from oligodendrocytes either early or late in their maturation resulted in striking, progressive changes in oligodendrocyte morphology, including extension of new processes and wrapping of inappropriate targets, such as neuronal somata and capillaries. Inappropriate myelination of neuronal somata has been observed after deletion of adhesive proteins (e.g., JAM2) from neurons (Redmond et al., 2016), expression of a mutant form of a cell adhesion protein (e.g., Cadm4) in oligodendrocytes (Elazar et al., 2019), or overexpression of MBP (Almeida et al., 2018). Similar aberrant myelination has been recently described in MS lesions (Neely et al., 2022), where TDP-43 mislocalization has also be observed (Masaki et al., 2020). The morphological changes exhibited by TDP-43-deficient oligodendrocytes suggests that they revert to a progrowth state (Grinspan et al., 1993; Lee et al., 2019), allowing them to overcome repulsive cues or lack of adhesion that normally prevents wrapping of nonaxonal structures.

Loss of TDP-43 leads to aberrant RNA splicing

TDP-43 maintains the integrity of the cellular transcriptome by regulating splicing of pre-mRNAs and suppressing incorporation of cryptic exons. By efficiently binding to UG microsatellite repeats within intronic sequences, TDP-43 ensures that spliceosomes skip over these regions during normal splicing (Ling et al., 2015). As the specificity of TDP-43 targets primarily depend on the location of these UG tandem repeats, TDP-43-dependent cryptic exons are both cell type and species specific (Jeong et al., 2017; Ling et al., 2015). By performing RNA sequencing of TDP-43-deficient oligodendrocytes purified from the brain, we uncovered a novel set of cryptic exons in mRNAs that encode proteins involved in oligodendrogenesis and myelination, changes that resulted from novel cassette insertion, exon extension, and alternative splicing. In case of Ermin, a cytoskeletal protein involved in oligodendrocyte morphogenesis (Brockschnieder et al., 2006), cryptic exon incorporation led to a pronounced decrease in protein expression; however, the phenotypic changes induced by loss of TDP-43 are not the same as that observed in Ermn KO mice (Wang et al., 2020; Ziaei et al., 2020). Aberrant splicing of Ermin mRNA is predicted to lead to a truncated N-terminal peptide (~amino acid 1–110) that may produce a dominant negative effect. Moreover, loss of TDP-43 was not selective for Ermin, but led to aberrant splicing of numerous myelin and oligodendrocyte genes (Figure 6F). Nfasc, which is misspliced in TDP-43-deficient Schwann cells (Chang et al., 2021), was not alternatively spliced in TDP-43-null oligodendrocytes, further confirming the cell-type-specific actions of TDP-43. The combination of gain and loss of function of the resultant proteins likely contribute to complex phenotype exhibited by these mutant oligodendrocytes.

Oligodendrocyte and myelin abnormalities have been reported in many neurodegenerative diseases known to present with TDP-43 proteinopathy (Kang et al., 2013; Masaki et al., 2020; Zhang et al., 2019). Although cytoplasmic aggregates of TDP-43 are not always present, nuclear clearance of TDP-43 and resulting loss of function is sufficient to cause dramatic alterations in pre-mRNA splicing (Sun et al., 2017). Further investigation of RNA splicing changes in oligodendrocytes in different neurodegenerative diseases may reveal unique pathological signatures associated with disease states that may help predict progression and identify novel therapeutic approaches for reducing the impact of impaired TDP-43 activity.

Materials and methods

Key resources table.

Reagent type (species) or resource Designation Source or reference Identifiers Additional information
Strain, strain background (Mus musculus, C57BL6) Pdgfra-CreER Kang et al., 2010
Strain, strain background (Mus musculus, C57BL6) Tardbp floxed Chiang et al., 2010
Strain, strain background (Mus musculus, Mixed) RCE (Rosa-CAG-LSL-EGFP) Sousa et al., 2009 JAX MMRRC stock #32,038
Strain, strain background (Mus musculus, C57BL6) Mobp-iCre This paper Generated and maintained by D.E. Bergles lab
Strain, strain background (Mus musculus, C57BL6) Mobp-iCreER This paper Generated and maintained by D.E. Bergles lab
Strain, strain background (Mus musculus, C57BL6) MogiCre Buch et al., 2005
Strain, strain background (Mus musculus, C57BL6) STOCK Tg (Mobp-EGFP) IN1Gsat/Mmucd MMRC RRID:MMRRC_030483- UCD Hughes et al., 2018
Antibody Anti-Aspartoacylase (ASPA) (rabbit polyclonal) Gentex RRID:AB_2036283 (1:1500)
Antibody Anti-GFP (chicken polyclonal) Aves lab RRID:AB_2307313 (1:1500)
Antibody Anti-MBP (mouse monoclonal) Sternberger RRID:AB_2564741 (1:2000)
Antibody Anti-NG2 (guinea pig serum) Generated in D.E. Bergles lab against entire NG2 protein Kang et al., 2013 (1:10,000)
Antibody Anti-Ki-67 (rabbit polyclonal) Abcam RRID:AB_443209 (1:1000)
Antibody Anti-GFP (goat polyclonal) Sicgen RRID:AB_2333099 (1:7500)
Antibody Anti-MBP (chicken polyclonal) Aves lab RRID:AB_2313550 (1:500)
Antibody Anti-GFAP (rabbit polyclonal) Agilent RRID:AB_10013482 (1:500)
Other Alexa Fluor 647 Isolectin GS-IB4 Thermo Fisher (1:200)
Antibody Anti-Aquaporin 4 (rabbit polyclonal) Sigma RRID:AB_1844967 (1:1500)
Antibody Anti-NeuN (mouse monoclonal) Millipore RRID:AB_2298772 (1:500)
Antibody Anti-Ermin (mouse monoclonal) Generated by E. Peles Lab Gift from E. Peles (1:1000)
Antibody Anti-Caspr (guinea pig polyclonal) Generated by M. Bhat Lab Gift from M. Bhat (1:1500)
Antibody Anti-βIV spectrin (rabbit polyclonal) Generated by M. Rasband Lab Gift from M. Rasband (1:300)
Antibody Anti-ChAT (goat polyclonal) Millipore RRID:AB_90650 (1:500)
Antibody Anti-CC1 (mouse monoclonal) Millipore RRID:AB_2242783 (1:50)
Antibody Anti-GAPDH (rabbit monoclonal) Cell Signalling RRID:AB_10622025 (1:1000)
Antibody Anti-Rabbit IgG conjugated to Cy3 or Cy5 (donkey polyclonal) Jackson Immuno RRID:AB_2313568RRID:AB_2340625 (1:2000)
Antibody Anti-Mouse IgG conjugated to Cy3 or Cy5 (donkey polyclonal) Jackson Immuno RRID:AB_2340817RRID:AB_2340820 (1:2000)
Antibody Anti-Guinea pig IgG conjugated to Cy3 or Cy5 (donkey polyclonal) Jackson Immuno RRID:AB_2340461RRID:AB_2340477 (1:2000)
Antibody Anti-Goat IgG conjugated to Alexa 488 or Cy3 (donkey polyclonal) Jackson Immuno RRID:AB_2340430RRID:AB_2340413 (1:2000)
Antibody Anti-Chicken IgG conjugated to Alexa 488 or Cy5 (donkey polyclonal) Jackson Immuno RRID:AB_2340376RRID:AB_2340347 (1:2000)
Software, algorithm ZEN Blue/Black Zeiss RRID:SCR_013672
Software, algorithm Fiji http://fiji.sc RRID:SCR_002285
Chemical compound, drug Tamoxifen Sigma
Chemical compound, drug Sunflower seed oil Sigma

Generation of Mobp-iCre and Mobp-iCreER mouse lines

iCreERT2 sequence was inserted into pBACe3.6_RP23-127H7 to generate Mobp-iCreERT2 BAC for injection in C57BL/6 background. Out of five PCR-positive founders, one of the founders yielded F1 and F2 generations where Cre recombination was independent of tamoxifen injection. Therefore, this line was then designated as a constitutive Mobp-iCre mouse line (line #10). Of the other founder lines, the line with highest tamoxifen-dependent recombination efficiency was selected and maintained as a conditional Mobp-iCreERT2 mouse line (lines #8, 16) (Figure 2—figure supplement 1).

Animal care and use

Both female and male mice were used for experiments and randomly assigned to experimental groups. Mice were maintained on a 12 hr light/dark cycle, housed in groups no larger than 5, and food and water were provided ad libitum. All animal experiments were performed in strict accordance with protocols approved by the Animal Care and Use Committee at Johns Hopkins University. All experiments were initially performed with a sample size of 3 (biological replicates) for quantification and statistical analyses, and power analysis was then performed to determine the minimum sample size to achieve sufficient statistical power to detect the effect of TDP-43 loss in different transgenic mouse lines at different timepoints. The following transgenic mouse lines were used in this study:

CreER Induction

To induce Tardbp genetic deletion and EGFP expression in the Pdgfra-CreER;Tardbpfloxed;RCE and Mobp-iCreER;Tardbpfloxed;RCE mice, P90 or P180–240 mice were injected with tamoxifen (Sigma) dissolved in sunflower seed oil (Sigma) and administered by intraperitoneal injection daily for five consecutive days at a dose of 100 mg/kg body weight. Mice were perfused 14, 30, 60, and 90 days from the last day of tamoxifen injection.

Cranial windows and in vivo two-photon microscopy

Cranial windows were prepared as previously described (Orthmann-Murphy et al., 2020). Briefly, 4- to 8-week-old mice were anesthetized with isoflurane (induction, 5%; maintenance, 1.5–2%, mixed with 0.4–1 l/min O2), and their body temperature was maintained at 37°C with a thermostat-controlled heating plate. The skin over the right hemisphere was removed and the skull cleaned. A 3 × 3 mm region of skull over motor cortex was removed using a high-speed dental drill. A piece of cover glass (VWR, No. 1) was placed in the craniotomy and sealed with VetBond (3 M), then dental cement (C&B Metabond) and a custom metal plate with a central hole was attached to the skull for head stabilization. In vivo imaging sessions began 3 weeks after cranial window procedure in order for the surgery-induced inflammation to subside. During imaging sessions, mice were anesthetized with isoflurane and immobilized by attaching the head plate to a custom stage. Images were collected using a Zeiss LSM 710 microscope equipped with a GaAsP detector using a mode-locked Ti:sapphire laser (Coherent Ultra) tuned to 920 nm.

Immunohistochemistry

Mice were deeply anesthetized with sodium pentobarbital (100 mg/kg) and perfused transcardially first with 15–20 ml room temperature PBS (pH 7.4) followed by 10 ml ice-cold 4% paraformaldehyde (PFA in 0.1 M phosphate buffer, pH 7.4). CNS tissues were dissected (e.g., optic nerve, brain, and spinal column) and postfixed in 4% PFA at 4°C for 4–6 or 12–20 hr depending on the antibodies to be used for immunohistochemistry. The tissues samples were transferred to 30% sucrose solution (in PBS, pH 7.4) for cryoprotection for at least two overnights before sectioning. Tissue samples were frozen in TissueTek and sectioned at 35 μm thickness on a cryostat (Thermo Scientific Microm HM 550) at −20°C. Tissue sections were collected into a 24-well plate with PBS with 0.1% NaN3 and kept in 4°C until use. Free-floating sections were preincubated in blocking solution (10% normal donkey serum, 0.3% Triton X-100 in PBS, pH 7.4) for 1 or 2 hr at room temperature, then incubated for 24–48 hr at 4°C or room temperature in primary antibody. Secondary antibody incubation was performed at room temperature for 2–4 hr. Sections were mounted on slides with Aqua Polymount (Polysciences). Images were acquired using a confocal laser-scanning microscope (Zeiss LSM 510 Meta; Zeiss LSM 800; Zeiss LSM 880). The following primary antibodies were used in this study: rabbit anti-ASPA (Genetex; RRID_AB_2036283), chicken anti-GFP (Aves lab; RRID:AB_2307313), goat anti-GFP (Sicgen; RRID:AB_2333099), mouse anti-MBP (Sternberger; RRID:AB_2564741), chicken anti-MBP (Aves lab; RRID:AB_2313550), rabbit anti-GFAP (Agilent; RRID:AB_10013482), Alexa Fluor 647 isolectin GS-IB4 (Thermo Fisher), rabbit anti-Aquaporin 4 (Sigma; RRID:AB_1844967), mouse anti-NeuN (Millipore; RRID:AB_2298772), mouse anti-CC1 (Millipore; RRID:AB_2242783), mouse anti-Ermin (Gift from E. Peles), guinea pig anti-Caspr (Gift from M. Bhat), rabbit anti-BIV-spectrin (Gift from M. Rasband), goat anti-ChAT (Millipore; RRID:AB_90650), guinea pig anti-NG2 (Generated in D.E. Bergles lab), and rabbit anti-Ki-67 (Abcam; RRID:AB_443209). Appropriate donkey secondary antibodies conjugated to Alexa Fluor 488, Cy3 or Alexa Fluor 546, and Cy5 or Alexa Fluor 647 were used at 1:1000–2000.

Transmission electron microscopy (TEM) and G ratio quantification

Samples were perfuse fixed with room temperature PBS and ‘Karlsson–Schultz’ buffer (2.5% glutaraldehyde, 4% formaldehyde and 0.5% NaCl in phosphate buffer pH 7.3) and postfixed at 4°C for two overnights. Subsequent TEM processing was performed according to a previously described protocol (Weil et al., 2019). For G ratio analysis 10 random micrographs covering an area of ~180 µm2 each were taken at a magnification of ×6000 using a LEO912 transmission electron microscope (Carl Zeiss Microscopy, Oberkochen, Germany) with an on-axis 2k CCD camera (TRS, Moorenweis, Germany). For random selection of axons the images were overlaid with a grid and axons on grid crossings were analyzed with a minimum of 100 axons per animal. For G ratio determination the area of the axon and the corresponding fiber including the myelin sheath were measured using Fiji/ImageJ (Schindelin et al., 2012) and the diameters derived assuming circular areas. The G ratios were calculated as a ratio between axonal diameter and total fiber diameter.

Image processing and analysis

Image stacks and time series were analyzed using FIJI/ImageJ. For figure presentation, image brightness and contrast levels were adjusted for clarity. Density and G ratio quantifications were performed by a blinded observer. Longitudinal image stacks were registered using FIJI plugin ‘Correct 3D Drift’ (Parslow et al., 2014; Orthmann-Murphy et al., 2020). Quantification of abnormal wrapping was performed on maximum intensity z-projection images. Wrapping of neuronal soma was determined by EGFP+ processes wrapping around NeuN+ neuronal somata, whereas that of blood vessels was determined by the ‘tube’-like structures made by EGFP+ oligodendrocyte processes.

Structural analysis of individual cortical oligodendrocytes

Cortices of MogiCre;Tardbpfloxed;Mobp-EGFP mice were flatmounted between glass slides, postfixed in 4% PFA for 12 hr at 4°C and transferred to 30% sucrose solution (in PBS, pH 7.4). Tissue was stored at 4°C for 48+ hr before sectioning. Flatmounted hemicortex were extracted, frozen in TissueTek, and sectioned at 40 µm thickness on a cryostat (Thermo Scientific Microm HM 550) at −20°C. Free-floating immunohistochemistry against MBP and EGFP was performed on the first section of the flatmount, which consists of the layer I of the cerebral cortex, as described previously (Orthmann-Murphy et al., 2020). High-resolution images were acquired using a confocal laser-scanning microscope (Zeiss LSM 880). All processes originating from the cell body, branch points, and individual myelin sheaths stained with EGFP and MBP were traced in FIJI using Simple Neurite Tracer (Longair et al., 2011). A smoothing function was used on the traced segments prior to length calculation to reduce tracing artifacts.

Clinical EAE behavioral scoring

Clinical EAE behavioral scores were obtained in a masked manner based on the preacquired videos of the animals, using the established standard scoring from 1 to 5; 0 = no signs of disease; 1 = loss of tail tonicity; 2 = loss of tail tonicity and mild paralysis of hindlimbs; 3 = paralysis of hindlimbs; 4 = hindlimbs paralysis and mild paralysis of forelimbs; and 5 = complete paralysis or death (Gharagozloo et al., 2021).

Statistical analysis

Statistical analyses were performed with GraphPad Prism 7 or Excel (Microsoft). All technical replicates (e.g., different brain sections for IHC) for each sample were averaged as a single data point. Significance was determined using one-way ANOVA test with Tukey’s correction for multiple comparisons or unpaired, two-tailed Student’s t-test. Each figure legend otherwise contains the statistical tests used to measure significance and the corresponding significance level (p value). n represents the number of animals (biological replicates) used in each experiment. Data are reported as mean ± standard error of the mean and p value <0.05 was considered statistically significant.

Fluorescence-activated cell sorting

Male and female Mobp-TDP43 and Mog-TDP43 mice aged at P30 were cardiac perfused with ice-cold 1× Hank's Balanced Salt Solution (HBSS) w/o Ca2+ and Mg2+. Only the cortex was dissected out for downstream processing and mechanically dissociated with a razor blade on ice. The Miltenyi Neural Tissue Dissociation kit was used to perform enzymatic dissociation of the tissue into a single-cell suspension, and Myelin Debris Removal solution (Miltenyi) to remove myelin debris. The cells were resuspended in FACS sorting buffer (5 ml of 1 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) + 2 ml of Fetal Bovine Serum (FBS) + 800 μl of 0.5 M EDTA (Ethylenediaminetetraacetic acid) in 200 ml HBSS w/o Ca2+, Mg2+) and filtered through 35 μm strainer. The cells were sorted for endogenous GFP fluorescence on BD FACS Aria IIu Cell Sorter using a 100 μm nozzle at the Ross Flow Cytometry Core Facility at Johns Hopkins University School of Medicine.

RNA isolation, cDNA library preparation, and sequencing

RNA was isolated from FACS purified oligodendrocytes (~5000 cells/sample) using QIAGEN RNeasy Micro Kit following the manufacturer’s instructions. cDNA was synthesized by using QIAGEN QuantiTect Reverse Transcription Kit. Due to low amount of cDNA, Nugen Single-cell RNAseq kit was used to generate cDNA libraries for 100 bp paired-end sequencing on Illumina HiSeq (70–100 million paired reads/sample).

Analysis of bulk RNA-Seq data

Reads were aligned to the latest mouse mm10 reference genome using the STAR spliced read aligner with default parameters. Total counts of read fragments aligned to known gene regions within the mouse mm10 RefSeq reference annotation were used as the basis for quantification of gene expression. Fragment counts were derived using HTS-seq program using mm10 Ensembl transcripts as the model. Various QC analyses were conducted to assess the quality of the data and to identify potential outliers (e.g., the level of mismatch rate, mapping rate to the whole genome, repeats, chromosomes, and key transcriptomic regions). Principal component analysis correction was performed to correct for batch effects and differences in sample RNA integrity number. Differentially expressed genes were identified using EdgeR Bioconductor package and ranked based on adjusted p values (false discovery rate) of <0.05.

RT-PCR

RNA was isolated from whole mouse brain tissue using ReliaPrep RNA Tissue Miniprep System (Promega) following the manufacturer’s instructions. cDNA was synthesized by using QIAGEN QuantiTect Reverse Transcription Kit. RT-PCR primers against normal Ermn and cryptic exon-specific Ermn transcripts were designed using Benchling and Primer3.

Western blotting

Whole mouse brain tissue was homogenized in 1.5 ml Eppendorf tube with a handheld homogenizer in Pierce RIPA buffer (Thermo Fisher) with Sodium Orthovanadate (Vanadate). After centrifugation at 4°C, supernatant was collected, and the protein concentration was determined using Pierce BCA Protein Assay Kit (Thermo Fisher). 50 μg of protein was loaded into each lane of Mini-Protean TGX gels (BioRad) and ran at 120 V for 1.5 hr. Protein was transferred onto Immobilon-FL PVDF Membrane (Millipore) at 100 V for 1.5 hr. Intercept (TBS) Blocking Buffer (Li-Cor) was used for blocking, and the membrane was incubated in primary antibody solution at 4°C overnight with gentle shaking. Mouse-Ermin (Mab160; raised against Ermin residues 1–261) and Rabbit-GAPDH (Cell Signaling) primary antibodies were used. IRDye 680RD Goat anti-Mouse IgG (H + L) (Li-Cor) and IRDye 800CW Goat anti-Rabbit IgG (H + L) (Li-Cor) were used as secondary antibodies for imaging on Odyssey Imaging Workstation (Li-Cor).

Acknowledgements

We thank M Pucak at the Multiphoton Imaging (MPI) Core in the Department of Neuroscience at Johns Hopkins for technical assistance, E Peles for gift of the mouse anti-Ermin primary antibody, M Rasband for anti-BIV-spectrin primary antibody, M Bhat for guinea pig anti-Caspr primary, and members of the Bergles lab for discussions. V Doze assisted in quantifying the myelinated axons in TEM images, and CL Call generated a diagram for Figure 3—figure supplement 3B. D Heo was supported by NINDS National Research Service Award (NRSA) predoctoral training fellowship (F31NS110204). GC Molina-Castro was supported by a National Science Foundation Graduate Research Fellowship (DGE-1746891). K-A Nave was supported by an ERC Advanced Grant (MyeliNANO) and DFG-TRR274. Funding was provided by grants from The National MS Society, Target ALS and the Dr. Miriam and Sheldon G Adelson Medical Research Foundation to DE Bergles and K-A Nave.

Funding Statement

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.

Contributor Information

Dwight E Bergles, Email: dbergles@jhmi.edu.

Beth Stevens, Boston Children's Hospital, United States.

Gary L Westbrook, Oregon Health and Science University, United States.

Funding Information

This paper was supported by the following grants:

  • National Institutes of Health R01 AG072305 to Dwight E Bergles.

  • National Multiple Sclerosis Society to Dwight E Bergles.

  • National Institutes of Health F31NS110204 to Dongeun Heo.

  • European Research Council MyeliNANO to Klaus-Armin Nave.

  • Deutsche Forschungsgemeinschaft DFG-TRR274 to Klaus-Armin Nave.

  • Target ALS to Dwight E Bergles.

  • Dr. Miriam and Sheldon G Adelson Medical Research Foundation to Dwight E Bergles.

  • Max-Planck-Institute of Experimental Medicine open access funding to Wiebke Möbius.

Additional information

Competing interests

No competing interests declared.

No competing interests declared.

Reviewing editor, eLife.

Author contributions

Data curation, Formal analysis, Methodology, Validation, Visualization, Writing – review and editing, Investigation, Project administration, Resources, Supervision, Writing - original draft.

Formal analysis, Methodology, Writing – review and editing, Project administration, Resources, Writing - original draft.

Formal analysis, Methodology, Visualization, Writing – review and editing, Resources, Writing - original draft.

Methodology, Writing – review and editing, Funding acquisition.

Funding acquisition, Writing - original draft.

Formal analysis, Writing – review and editing, Conceptualization, Investigation, Writing - original draft.

Formal analysis, Methodology, Visualization, Writing – review and editing, Resources, Writing - original draft.

Data curation, Writing – review and editing, Investigation, Writing - original draft.

Data curation, Validation, Visualization, Writing – review and editing, Conceptualization, Funding acquisition, Investigation, Resources, Supervision, Writing - original draft.

Ethics

This study was performed in strict accordance with the recommendations by the Institutional Animal Care and Use Committee (IACUC) of the Johns Hopkins School of Medicine under protocols (MO17M338, MO17M268, MO20M206, and MO20M344). All survival surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering. All terminal experiments were carried out under sodium pentobarbital anesthesia.

Additional files

Supplementary file 1. Differential gene expression of TDP-43 KO oligodendrocytes.

Excel file of bulk RNA-Seq that includes average FPKM of each gene, log fold change (FC), p value, and false discovery rate (FDR) for the following comparisons: (1) Mog-TDP43-WT vs. Mobp-TDP43-WT, (2) Mog-TDP43-KO vs. Mobp-TDP43-KO, (3). Mog-TDP43-KO vs. Mog-TDP43-WT, (4) Mobp-TDP43-KO vs. Mobp-TDP43-WT, and (5) TDP43-WT vs. TDP43-KO.

elife-75230-supp1.xlsx (3.3MB, xlsx)
Transparent reporting form

Data availability

Bulk RNA-seq data of P30 FACS-isolated oligodendrocytes from Mobp-TDP43 and Mog-TDP43 mouse lines has been deposited to GEO (GSE188903). Processed data, including the raw count number, normalized counts, and FPKM values, are provided as Supplementary Data (Supplementary file 1. Differential gene expression of TDP-43 KO oligodendrocytes).

The following dataset was generated:

Heo D, Ling JP, Molina-Castro GC, Langseth AJ, Waisman A, Nave K-A, Möbius W, Wong PC, Bergles DE. 2021. Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43. NCBI Gene Expression Omnibus. GSE188903

The following previously published datasets were used:

Hrvatin S, Hochbaum DR, Nagy MA, Cicconet M, Robertson K, Cheadle L, Zilionis R, Ratner A, Borges-Monroy R, Klein AM, Sabatini BL, Greenberg ME. 2018. Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. NCBI- GSE102827.

Marques S, Zeisel A, Codeluppi S, van Bruggen D, Falcao AM, Xiao L, Li H, Haring M, Hochgerner H, Romanov RA, Gyllborg D, Manchado AM, Manno GL, Lonnerberg P, Floriddia EM, Rezayee F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G. 2016. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. NCBI Gene Expression Omnibus. GSE75330

References

  1. Almeida RG, Czopka T, ffrench-Constant C, Lyons DA. Individual Axons Regulate the Myelinating Potential of Single Oligodendrocytes in Vivo. Development. 2011;138:4443–4450. doi: 10.1242/dev.071001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almeida RG, Pan S, Cole KLHH, Williamson JM, Early JJ, Czopka T, Klingseisen A, Chan JR, Lyons DA. Myelination of Neuronal Cell Bodies When Myelin Supply Exceeds Axonal Demand. Current Biology. 2018;28:1296–1305. doi: 10.1016/j.cub.2018.02.068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bacmeister CM, Barr HJ, McClain CR, Thornton MA, Nettles D, Welle CG, Hughes EG. Motor Learning Promotes Remyelination via New and Surviving Oligodendrocytes. Nature Neuroscience. 2020;23:819–831. doi: 10.1038/s41593-020-0637-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baracskay KL, Duchala CS, Miller RH, Macklin WB, Trapp BD. Oligodendrogenesis Is Differentially Regulated in Gray and White Matter of Jimpy Mice. Journal of Neuroscience Research. 2002;70:645–654. doi: 10.1002/jnr.10418. [DOI] [PubMed] [Google Scholar]
  5. Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, Handa V, Döderlein G. Gadd45a Promotes Epigenetic Gene Activation by Repair-Mediated DNA Demethylation. Nature. 2007;445:671–675. doi: 10.1038/nature05515. [DOI] [PubMed] [Google Scholar]
  6. Baxi EG, DeBruin J, Jin J, Strasburger HJ, Smith MD, Orthmann-Murphy JL, Schott JT, Fairchild AN, Bergles DE, Calabresi PA. Lineage Tracing Reveals Dynamic Changes in Oligodendrocyte Precursor Cells Following Cuprizone-Induced Demyelination. Glia. 2017;65:2087–2098. doi: 10.1002/glia.23229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, Götz M, Dimou L. Dynamic Changes in Myelin Aberrations and Oligodendrocyte Generation in Chronic Amyloidosis in Mice and Men. Glia. 2013;61:273–286. doi: 10.1002/glia.22432. [DOI] [PubMed] [Google Scholar]
  8. Benamer N, Vidal M, Balia M, Angulo MC. Myelination of Parvalbumin Interneurons Shapes the Function of Cortical Sensory Inhibitory Circuits. Nature Communications. 2020;11:1–14. doi: 10.1038/s41467-020-18984-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bergles DE, Richardson WD. Oligodendrocyte Development and Plasticity. Cold Spring Harbor Perspectives in Biology. 2015;8:a020453. doi: 10.1101/cshperspect.a020453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Birey F, Kloc M, Chavali M, Hussein I, Wilson M, Christoffel DJ, Chen T, Frohman MA, Robinson JK, Russo SJ, Maffei A, Aguirre A. Genetic and Stress-Induced Loss of NG2 Glia Triggers Emergence of Depressive-like Behaviors through Reduced Secretion of FGF2. Neuron. 2015;88:941–956. doi: 10.1016/j.neuron.2015.10.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brockschnieder D, Sabanay H, Riethmacher D, Peles E. Ermin, a Myelinating Oligodendrocyte-Specific Protein That Regulates Cell Morphology. The Journal of Neuroscience. 2006;26:757–762. doi: 10.1523/JNEUROSCI.4317-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Lee FCY, Masino L, Qi YA, Bryce-Smith S, Bampton A, Gatt A, Phatnani H, Schiavo G, Fisher EMC, Raj T, Secrier M, Lashley T, Ule J, Buratti E, Humphrey J, Ward ME, Fratta P, NYGC ALS Consortium Common ALS/FTD Risk Variants in UNC13A Exacerbate Its Cryptic Splicing and Loss upon TDP-43 Mislocalization. bioRxiv. 2021 doi: 10.1101/2021.04.02.438170. [DOI]
  13. Buch T, Heppner FL, Tertilt C, Heinen TJAJ, Kremer M, Wunderlich FT, Jung S, Waisman A. A Cre-Inducible Diphtheria Toxin Receptor Mediates Cell Lineage Ablation after Toxin Administration. Nature Methods. 2005;2:419–426. doi: 10.1038/nmeth762. [DOI] [PubMed] [Google Scholar]
  14. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions. The Journal of Neuroscience. 2000;20:6404–6412. doi: 10.1523/JNEUROSCI.20-17-06404.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chang KJ, Agrawal I, Vainshtein A, Ho WY, Xin W, Tucker-Kellogg G, Susuki K, Peles E, Ling SC, Chan JR. TDP-43 Maximizes Nerve Conduction Velocity by Repressing a Cryptic Exon for Paranodal Junction Assembly in Schwann Cells. eLife. 2021;10:e64456. doi: 10.7554/eLife.64456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-Regulates Tbc1d1, a Gene Linked to Obesity, and Alters Body Fat Metabolism. PNAS. 2010;107:16320–16324. doi: 10.1073/pnas.1002176107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dang TC, Ishii Y, Nguyen VD, Yamamoto S, Hamashima T, Okuno N, Nguyen QL, Sang Y, Ohkawa N, Saitoh Y, Shehata M, Takakura N, Fujimori T, Inokuchi K, Mori H, Andrae J, Betsholtz C, Sasahara M. Powerful Homeostatic Control of Oligodendroglial Lineage by PDGFRα in Adult Brain. Cell Reports. 2019;27:1073–1089. doi: 10.1016/j.celrep.2019.03.084. [DOI] [PubMed] [Google Scholar]
  18. Dawson MRL, Polito A, Levine JM, Reynolds R. NG2-Expressing Glial Progenitor Cells: An Abundant and Widespread Population of Cycling Cells in the Adult Rat CNS. Molecular and Cellular Neurosciences. 2003;24:476–488. doi: 10.1016/s1044-7431(03)00210-0. [DOI] [PubMed] [Google Scholar]
  19. de Faria O, Jr, Dhaunchak AS, Kamen Y, Roth AD, Kuhlmann T, Colman DR, Kennedy TE. TMEM10 Promotes Oligodendrocyte Differentiation and Is Expressed by Oligodendrocytes in Human Remyelinating Multiple Sclerosis Plaques. Scientific Reports. 2019;9:1–12. doi: 10.1038/s41598-019-40342-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early Oligodendrocyte/Myelin Pathology in Alzheimer’s Disease Mice Constitutes a Novel Therapeutic Target. The American Journal of Pathology. 2010;177:1422–1435. doi: 10.2353/ajpath.2010.100087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Donde A, Sun M, Ling JP, Braunstein KE, Pang B, Wen X, Cheng X, Chen L, Wong PC. Splicing Repression Is a Major Function of TDP-43 in Motor Neurons. Acta Neuropathologica. 2019;138:813–826. doi: 10.1007/s00401-019-02042-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Elazar N, Vainshtein A, Golan N, Vijayaragavan B, Schaeren-Wiemers N, Eshed-Eisenbach Y, Peles E. Axoglial Adhesion by Cadm4 Regulates CNS Myelination. Neuron. 2019;101:224–231. doi: 10.1016/j.neuron.2018.11.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fields R. White Matter in Learning, Cognition and Psychiatric Disorders. Trends in Neurosciences. 2008;31:361–370. doi: 10.1016/j.tins.2008.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gharagozloo M, Smith MD, Jin J, Garton T, Taylor M, Chao A, Meyers K, Kornberg MD, Zack DJ, Ohayon J, Calabresi BA, Reich DS, Eberhart CG, Pardo CA, Kemper C, Whartenby KA, Calabresi PA. Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation. Acta Neuropathologica. 2021;142:899–915. doi: 10.1007/s00401-021-02366-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gibson EM, Purger D, Mount CW, Goldstein AK, Lin GL, Wood LS, Inema I, Miller SE, Bieri G, Zuchero JB, Barres BA, Woo PJ, Vogel H, Monje M. Neuronal Activity Promotes Oligodendrogenesis and Adaptive Myelination in the Mammalian Brain. Science (New York, N.Y.) 2014;344:1252304. doi: 10.1126/science.1252304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Grinspan JB, Stern JL, Franceschini B, Pleasure D. Trophic Effects of Basic Fibroblast Growth Factor (BFGF) on Differentiated Oligodendroglia: A Mechanism for Regeneration of the Oligodendroglial Lineage. Journal of Neuroscience Research. 1993;36:672–680. doi: 10.1002/JNR.490360608. [DOI] [PubMed] [Google Scholar]
  27. Gundersen GA, Vindedal GF, Skare Ø, Nagelhus EA. Evidence That Pericytes Regulate Aquaporin-4 Polarization in Mouse Cortical Astrocytes. Brain Structure and Function. 2014;219:2181–2186. doi: 10.1007/S00429-013-0629-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. He D, Wang J, Lu Y, Deng Y, Zhao C, Xu L, Chen Y, Hu YC, Zhou W, Lu QR. LncRNA Functional Networks in Oligodendrocytes Reveal Stage-Specific Myelination Control by an LncOL1/Suz12 Complex in the CNS. Neuron. 2017;93:362–378. doi: 10.1016/j.neuron.2016.11.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hrvatin S, Hochbaum DR, Nagy MA, Cicconet M, Robertson K, Cheadle L, Zilionis R. Single-Cell Analysis of Experience-Dependent Transcriptomic States in the Mouse Visual Cortex. Nature Neuroscience. 2018;21:120–129. doi: 10.1038/s41593-018-0112-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hughes EG, Kang SH, Fukaya M, Bergles DE. Oligodendrocyte Progenitors Balance Growth with Self-Repulsion to Achieve Homeostasis in the Adult Brain. Nature Neuroscience. 2013;16:668–676. doi: 10.1038/nn.3390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hughes EG, Orthmann-Murphy JL, Langseth AJ, Bergles DE. Myelin Remodeling through Experience-Dependent Oligodendrogenesis in the Adult Somatosensory Cortex. Nature Neuroscience. 2018;21:696–706. doi: 10.1038/s41593-018-0121-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Humphrey J, Emmett W, Fratta P, Isaacs AM, Plagnol V. Quantitative Analysis of Cryptic Splicing Associated with TDP-43 Depletion. BMC Medical Genomics. 2017;10:1. doi: 10.1186/s12920-017-0274-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Iguchi Y, Katsuno M, Niwa J, Takagi S, Ishigaki S, Ikenaka K, Kawai K. Loss of TDP-43 Causes Age-Dependent Progressive Motor Neuron Degeneration. Brain: A Journal of Neurology. 2013;136:1371–1382. doi: 10.1093/BRAIN/AWT029. [DOI] [PubMed] [Google Scholar]
  34. Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ, Shaw PJ. Molecular Pathology and Genetic Advances in Amyotrophic Lateral Sclerosis: An Emerging Molecular Pathway and the Significance of Glial Pathology. Acta Neuropathologica. 2011;122:657–671. doi: 10.1007/s00401-011-0913-0. [DOI] [PubMed] [Google Scholar]
  35. Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, Traynor BJ, LaClair KD, Lloyd TE, Wong PC. Tdp-43 Cryptic Exons Are Highly Variable between Cell Types. Molecular Neurodegeneration. 2017;12:1. doi: 10.1186/s13024-016-0144-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2+ CNS Glial Progenitors Remain Committed to the Oligodendrocyte Lineage in Postnatal Life and Following Neurodegeneration. Neuron. 2010;68:668–681. doi: 10.1016/j.neuron.2010.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, Rothstein JD, Bergles DE. Degeneration and Impaired Regeneration of Gray Matter Oligodendrocytes in Amyotrophic Lateral Sclerosis. Nature Neuroscience. 2013;16:571–579. doi: 10.1038/nn.3357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kapeli K, Martinez FJ, Yeo GW. Genetic Mutations in RNA-Binding Proteins and Their Roles in ALS. Human Genetics. 2017;136:1193–1214. doi: 10.1007/s00439-017-1830-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Kirby BB, Takada N, Latimer AJ, Shin J, Carney TJ, Kelsh RN, Appel B. In Vivo Time-Lapse Imaging Shows Dynamic Oligodendrocyte Progenitor Behavior during Zebrafish Development. Nature Neuroscience. 2006;9:1506–1511. doi: 10.1038/nn1803. [DOI] [PubMed] [Google Scholar]
  40. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave K-A. Disruption of Cnp1 Uncouples Oligodendroglial Functions in Axonal Support and Myelination. Nature Genetics. 2003;33:366–374. doi: 10.1038/ng1095. [DOI] [PubMed] [Google Scholar]
  41. Larson VA, Mironova Y, Vanderpool KG, Waisman A, Rash JE, Agarwal A, Bergles DE. Oligodendrocytes Control Potassium Accumulation in White Matter and Seizure Susceptibility. eLife. 2018;7:e34829. doi: 10.7554/eLife.34829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lee EB, Lee VM-Y, Trojanowski JQ. Gains or Losses: Molecular Mechanisms of TDP43-Mediated Neurodegeneration. Nature Reviews. Neuroscience. 2011;13:38–50. doi: 10.1038/nrn3121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lee S, Leach MK, Redmond SA, Chong SYC, Mellon SH, Tuck SJ, Feng Z-Q, Corey JM, Chan JR. A Culture System to Study Oligodendrocyte Myelination Processes Using Engineered Nanofibers. Nature Methods. 2012;9:917–922. doi: 10.1038/nmeth.2105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lee H, Thacker S, Sarn N, Dutta R, Eng C. Constitutional Mislocalization of Pten Drives Precocious Maturation in Oligodendrocytes and Aberrant Myelination in Model of Autism Spectrum Disorder. Translational Psychiatry. 2019;9:13. doi: 10.1038/s41398-018-0364-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lieu CA, Chinta SJ, Rane A, Andersen JK. Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease. PLOS ONE. 2013;8:e54200. doi: 10.1371/journal.pone.0054200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, Cleveland DW. ALS-Associated Mutations in TDP-43 Increase Its Stability and Promote TDP-43 Complexes with FUS/TLS. PNAS. 2010;107:13318–13323. doi: 10.1073/pnas.1008227107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 Repression of Nonconserved Cryptic Exons Is Compromised in ALS-FTD. Science (New York, N.Y.) 2015;349:650–655. doi: 10.1126/science.aab0983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Longair MH, Baker DA, Armstrong JD. Simple neurite tracer: open source software for reconstruction, visualization and analysis of neuronal processes. Bioinformatics (Oxford, England) 2011;27:2453–2454. doi: 10.1093/bioinformatics/btr390. [DOI] [PubMed] [Google Scholar]
  49. Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Rodriguez CM, Schmidt HB, Cummings BB, Wyatt DW, Kurylo K, Miller G, Mekhoubad S, Sallee N, Jansen-West K, Cook CN, Pickles S, Oskarsson B, Graff-Radford NR, Boeve BF, Knopman DS, Petersen RC, Dickson DW, Green EM, Seeley WW, Petrucelli L, Gitler AD. TDP-43 Represses Cryptic Exon Inclusion in FTD/ALS Gene UNC13A. bioRxiv. 2021 doi: 10.1101/2021.04.02.438213. [DOI] [PMC free article] [PubMed]
  50. Marques S, Zeisel A, Codeluppi S, van Bruggen D, Mendanha Falcão A, Xiao L, Li H, Häring M, Hochgerner H, Romanov RA, Gyllborg D, Muñoz Manchado A, La Manno G, Lönnerberg P, Floriddia EM, Rezayee F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G. Oligodendrocyte Heterogeneity in the Mouse Juvenile and Adult Central Nervous System. Science (New York, N.Y.) 2016;352:1326–1329. doi: 10.1126/science.aaf6463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Masaki K, Sonobe Y, Ghadge G, Pytel P, Lépine P, Pernin F, Cui QL, Antel JP, Zandee S, Prat A, Roos RP. RNA-Binding Protein Altered Expression and Mislocalization in MS. Neurology(R) Neuroimmunology & Neuroinflammation. 2020;7:704. doi: 10.1212/NXI.0000000000000704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Mei F, Christin Chong SY, Chan JR. Myelin-Based Inhibitors of Oligodendrocyte Myelination: Clues from Axonal Growth and Regeneration. Neuroscience Bulletin. 2013;29:177–188. doi: 10.1007/s12264-013-1319-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Müller C, Bauer NM, Schäfer I, White R. Making Myelin Basic Protein -from MRNA Transport to Localized Translation. Frontiers in Cellular Neuroscience. 2013;7:169. doi: 10.3389/fncel.2013.00169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Neely SA, Williamson JM, Klingseisen A, Zoupi L, Early JJ, Williams A, Lyons DA. New Oligodendrocytes Exhibit More Abundant and Accurate Myelin Regeneration than Those That Survive Demyelination. Nature Neuroscience. 2022;10:1009. doi: 10.1038/s41593-021-01009-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM-Y. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science (New York, N.Y.) 2006;314:130–133. doi: 10.1126/science.1134108. [DOI] [PubMed] [Google Scholar]
  56. Oluich L-J, Stratton JAS, Xing YL, Ng SW, Cate HS, Sah P, Windels F, Kilpatrick TJ, Merson TD. Targeted Ablation of Oligodendrocytes Induces Axonal Pathology Independent of Overt Demyelination. The Journal of Neuroscience. 2012;32:8317–8330. doi: 10.1523/JNEUROSCI.1053-12.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Orthmann-Murphy J, Call CL, Molina-Castro GC, Hsieh YC, Rasband MN, Calabresi PA, Bergles DE. Remyelination Alters the Pattern of Myelin in the Cerebral Cortex. eLife. 2020;9:e56621. doi: 10.7554/eLife.56621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VM-Y, Trojanowski JQ, Spires-Jones T, Schulz PE, Rajendran L. TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron. 2017;95:297–308. doi: 10.1016/j.neuron.2017.05.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Parslow A, Cardona A, Bryson-Richardson RJ. Sample Drift Correction Following 4D Confocal Time-Lapse Imaging. Journal of Visualized Experiments. 2014;10:86. doi: 10.3791/51086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Penderis J, Shields SA, Franklin RJM. Impaired Remyelination and Depletion of Oligodendrocyte Progenitors Does Not Occur Following Repeated Episodes of Focal Demyelination in the Rat Central Nervous System. Brain. 2003;126:1382–1391. doi: 10.1093/brain/awg126. [DOI] [PubMed] [Google Scholar]
  61. Peng AYT, Agrawal I, Ho WY, Yen YC, Pinter AJ, Liu J, Phua QXC, Koh KB, Chang JC, Sanford E, Man JHK, Wong P, Gutmann DH, Tucker-Kellogg G, Ling SC. Loss of TDP-43 in Astrocytes Leads to Motor Deficits by Triggering A1-like Reactive Phenotype and Triglial Dysfunction. PNAS. 2020;117:29101–29112. doi: 10.1073/pnas.2007806117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Petasny M, Bentata M, Pawellek A, Baker M, Kay G, Salton M. Splicing to Keep Cycling: The Importance of Pre-MRNA Splicing during the Cell Cycle. Trends in Genetics. 2021;37:266–278. doi: 10.1016/j.tig.2020.08.013. [DOI] [PubMed] [Google Scholar]
  63. Phan BN, Bohlen JF, Davis BA, Ye Z, Chen H-Y, Mayfield B, Sripathy SR, Cerceo Page S, Campbell MN, Smith HL, Gallop D, Kim H, Thaxton CL, Simon JM, Burke EE, Shin JH, Kennedy AJ, Sweatt JD, Philpot BD, Jaffe AE, Maher BJ. A Myelin-Related Transcriptomic Profile Is Shared by Pitt–Hopkins Syndrome Models and Human Autism Spectrum Disorder. Nature Neuroscience. 2020;23:375–385. doi: 10.1038/s41593-019-0578-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Philips T, Mironova YA, Jouroukhin Y, Chew J, Vidensky S, Farah MH, Pletnikov MV, Bergles DE, Morrison BM, Rothstein JD. MCT1 Deletion in Oligodendrocyte Lineage Cells Causes Late-Onset Hypomyelination and Axonal Degeneration. Cell Reports. 2021;34:108610. doi: 10.1016/j.celrep.2020.108610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Purice MD, Taylor JP. Linking HnRNP Function to ALS and FTD Pathology. Frontiers in Neuroscience. 2018;12:326. doi: 10.3389/fnins.2018.00326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Redmond SA, Mei F, Eshed-Eisenbach Y, Osso LA, Leshkowitz D, Shen YAA, Kay JN. Somatodendritic Expression of JAM2 Inhibits Oligodendrocyte Myelination. Neuron. 2016;91:824–836. doi: 10.1016/j.neuron.2016.07.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Rohan Z, Matej R, Rusina R, Kovacs GG. Oligodendroglial Response in the Spinal Cord in TDP-43 Proteinopathy with Motor Neuron Involvement. Neuro-Degenerative Diseases. 2014;14:117–124. doi: 10.1159/000362929. [DOI] [PubMed] [Google Scholar]
  68. Rosenberg SS, Kelland EE, Tokar E, Torre A, Chan JR. The Geometric and Spatial Constraints of the Microenvironment Induce Oligodendrocyte Differentiation. PNAS. 2008;105:14662–14667. doi: 10.1073/pnas.0805640105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Salapa HE, Hutchinson C, Popescu BF, Levin MC. Neuronal RNA-Binding Protein Dysfunction in Multiple Sclerosis Cortex. Annals of Clinical and Translational Neurology. 2020;7:1214–1224. doi: 10.1002/acn3.51103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: An Open-Source Platform for Biological-Image Analysis. Nature Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, Yu G. TDP-43 Is a Developmentally Regulated Protein Essential for Early Embryonic Development. Journal of Biological Chemistry. 2010;285:6826–6834. doi: 10.1074/jbc.M109.061846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sousa VH, Miyoshi G, Hjerling-Leffler J, Karayannis T, Fishell G. Characterization of Nkx6-2-Derived Neocortical Interneuron Lineages. Cerebral Cortex. 2009;19:BHP038. doi: 10.1093/CERCOR/BHP038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, Pletnikova O, Troncoso JC, Wong PC, Chen LL. Cryptic Exon Incorporation Occurs in Alzheimer’s Brain Lacking TDP-43 Inclusion but Exhibiting Nuclear Clearance of TDP-43. Acta Neuropathologica. 2017;133:923–931. doi: 10.1007/s00401-017-1701-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Tognatta R, Sun W, Goebbels S, Nave KA, Nishiyama A, Schoch S, Dimou L, Dietrich D. Transient Cnp expression by early progenitors causes Cre-Lox-based reporter lines to map profoundly different fates. Glia. 2017;65:342–359. doi: 10.1002/glia.23095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Traka M, Podojil JR, Mccarthy DP, Miller SD, Popko B. Oligodendrocyte Death Results in Immune-Mediated CNS Demyelination. Nature Neuroscience. 2015;19:65–74. doi: 10.1038/nn.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Tripathi RB, Jackiewicz M, McKenzie IA, Kougioumtzidou E, Grist M, Richardson WD. Remarkable Stability of Myelinating Oligodendrocytes in Mice. Cell Reports. 2017;21:316–323. doi: 10.1016/j.celrep.2017.09.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Viganò F, Möbius W, Götz M, Dimou L. Transplantation Reveals Regional Differences in Oligodendrocyte Differentiation in the Adult Brain. Nature Neuroscience. 2013;16:1370–1372. doi: 10.1038/nn.3503. [DOI] [PubMed] [Google Scholar]
  78. Walker AK, Daniels CML, Goldman JE, Trojanowski JQ, Lee VM-Y, Messing A. Astrocytic TDP-43 Pathology in Alexander Disease. The Journal of Neuroscience. 2014;34:6448–6458. doi: 10.1523/JNEUROSCI.0248-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Wang J, Ho WY, Lim K, Feng J, Tucker-Kellogg G, Nave KA, Ling SC. Cell-Autonomous Requirement of TDP-43, an ALS/FTD Signature Protein, for Oligodendrocyte Survival and Myelination. PNAS. 2018;115:E10941–E10950. doi: 10.1073/pnas.1809821115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Wang S, Wang T, Liu T, Xie R-G, Zhao X-H, Wang L, Yang Q, Jia L-T, Han J. Ermin Is a P116 RIP -Interacting Protein Promoting Oligodendroglial Differentiation and Myelin Maintenance. Glia. 2020;68:2264–2276. doi: 10.1002/glia.23838. [DOI] [PubMed] [Google Scholar]
  81. Warraich ST, Yang S, Nicholson GA, Blair IP. TDP-43: A DNA and RNA Binding Protein with Roles in Neurodegenerative Diseases. The International Journal of Biochemistry & Cell Biology. 2010;42:1606–1609. doi: 10.1016/j.biocel.2010.06.016. [DOI] [PubMed] [Google Scholar]
  82. Weil MT, Ruhwedel T, Meschkat M, Sadowski B, Möbius W. Transmission Electron Microscopy of Oligodendrocytes and Myelin. Methods in Molecular Biology (Clifton, N.J.) 2019;1936:343–375. doi: 10.1007/978-1-4939-9072-6_20. [DOI] [PubMed] [Google Scholar]
  83. Wiesner D, Tar L, Linkus B, Chandrasekar A, Olde Heuvel F, Dupuis L, Tsao W, Wong PC, Ludolph A, Roselli F. Reversible Induction of TDP-43 Granules in Cortical Neurons after Traumatic Injury. Experimental Neurology. 2018;299:15–25. doi: 10.1016/j.expneurol.2017.09.011. [DOI] [PubMed] [Google Scholar]
  84. Wong M, Martin LJ. Skeletal Muscle-Restricted Expression of Human SOD1 Causes Motor Neuron Degeneration in Transgenic Mice. Human Molecular Genetics. 2010;19:2284–2302. doi: 10.1093/hmg/ddq106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Wu LS, Cheng WC, Chen CY, Wu MC, Wang YC, Tseng YH, Chuang TJ, Shen CKJ. Transcriptomopathies of Pre- and Post-Symptomatic Frontotemporal Dementia-like Mice with TDP-43 Depletion in Forebrain Neurons. Acta Neuropathologica Communications. 2019;7:50. doi: 10.1186/s40478-019-0674-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Xiao L, Ohayon D, McKenzie IA, Sinclair-Wilson A, Wright JL, Fudge AD, Emery B, Li H, Richardson WD. Rapid Production of New Oligodendrocytes Is Required in the Earliest Stages of Motor-Skill Learning. Nature Neuroscience. 2016;19:1210–1217. doi: 10.1038/nn.4351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Xing YL, Röth PT, Stratton JA, Chuang BH, Danne J, Ellis SL, Ng SW, Kilpatrick TJ, Merson TD. Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte regeneration and remyelination. The Journal of Neuroscience. 2014;34:14128–14146. doi: 10.1523/JNEUROSCI.3491-13.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Xing YL, Chuang BHA, Poh J, Moradi K, Mitew S, Kilpatrick TJ, Osanai Y, Merson TD. A Novel Pharmacogenetic Model for Highly Efficient Ablation of Oligodendrocyte Progenitor Cells in the Adult Mouse CNS. bioRxiv. 2021 doi: 10.1101/2021.05.13.443012. [DOI] [PMC free article] [PubMed]
  89. Xu H, Dzhashiashvili Y, Shah A, Kunjamma RB, Weng Y-L, Elbaz B, Fei Q, Jones JS, Li YI, Zhuang X, Ming G-L, He C, Popko B. M 6 A MRNA Methylation Is Essential for Oligodendrocyte Maturation and CNS Myelination. Neuron. 2020;105:293–309. doi: 10.1016/j.neuron.2019.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, Tan W, Salameh J, McKenna-Yasek DM, Smith T, Peng L, Moore MJ, Brown RH, Cai H, Xu Z. Partial Loss of TDP-43 Function Causes Phenotypes of Amyotrophic Lateral Sclerosis. PNAS. 2014;111:E1121–E1129. doi: 10.1073/pnas.1322641111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Zhang P, Kishimoto Y, Grammatikakis I, Gottimukkala K, Cutler RG, Zhang S, Abdelmohsen K, Bohr VA, Misra Sen J, Gorospe M, Mattson MP. Senolytic Therapy Alleviates Aβ-Associated Oligodendrocyte Progenitor Cell Senescence and Cognitive Deficits in an Alzheimer’s Disease Model. Nature Neuroscience. 2019;22:719–728. doi: 10.1038/s41593-019-0372-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, Appel SH. TDP-43 Activates Microglia through NF-ΚB and NLRP3 Inflammasome. Experimental Neurology. 2015;273:24–35. doi: 10.1016/j.expneurol.2015.07.019. [DOI] [PubMed] [Google Scholar]
  93. Ziaei A, Garcia-Miralles M, Radulescu CI, Sidik H, Silvin A, Bae HG, Bonnard C, Mohammad Yusof NAB, Bardile CF, Tan LJ, Ng AYJ, Tohari S, Dehghani L, Venkatesh B, Langley SR, Shaygannejad V, Reversade B, Jung S, Ginhoux F, Pouladi MA. Ermin Deficiency as an Inside-out Model of Inflammatory Dysmyelination. bioRxiv. 2020 doi: 10.1101/2020.06.16.154781. [DOI]

Editor's evaluation

Beth Stevens 1

Heo et al., 2021 investigated the role of the DNA/RNA-binding protein TDP-43 on oligodendrocyte maturation and showed that deletion of this protein induces deleterious effects on oligodendrocyte function in transgenic mouse models. These findings are exciting and support TDP-43 as a key regulator of oligodendrocyte function which may go awry in neurodegenerative disorders.

Decision letter

Editor: Beth Stevens1
Reviewed by: Maria D Purice2

Our editorial process produces two outputs: i) public reviews designed to be posted alongside the preprint for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Gary Westbrook as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Maria D Purice (Reviewer #3).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission with specific attention to the essential revisions.

Essential revisions:

The majority of the comments are focused on the clarity of the written document, as well as suggestions for making the figures more informative as well as specific recommendations for increasing the clarity of the figures and providing quantification of a few of the figures.

– There were a few additional experimental data requested centered on reporter data on recombination efficiency (see reviewer 2 point #3)- and neurofascin splicing (see rev 2 point 5).

– Please provide more details and quantification of the immunohistochemistry images shown as noted by reviewer 1 in legends and methods (in particular Figures 4, 5).

– Please address reviewer 3 comment regarding potential loss of OPC identity. All reviewers agreed this is important especially since one marker (NG2) was used to define OPCs. Because the absence of TDP-43 alters splicing, it is possible that NG2 is not being expressed. This could also help explain the lack of astrogliosis.

Reviewer #1 (Recommendations for the authors):

Major Strengths:

• Mog-TDP43 and Mobp-TDP43 KO mice represent useful tools for the field to study early and late stages of oligodendrocyte maturation

• The stage-dependent role of TDP-43 in oligodendrocyte maturation, morphology, and function is particularly novel.

• Transcriptomic analysis (Figure 6) is particularly strong, showing that TDP-43 KO oligodendrocytes exhibit missplicing of cytoskeletal-associated genes

Major Weaknesses:

• Very minimal quantification of immunohistochemistry images (Figure 4 in particular). Quantification of all images must be included with details in methods/legends

• Several figures could be split up into separate figures to enhance clarity. Schematics should also be included in separate figures to provide additional visuals of experiments

• No stain of TDP-43 in immunohistochemistry images. Please address.

• No quantification of behavior/hindlimb weakness (Figure 5)

• Narrative is lost through the vast amount of data shown, especially within each figure

• Figure 3 axon thinning and density could be shown via A,B,D,E,F and without C and G

• Figure 4 does not need examples of abnormal structures (could be put in supplement), and lacks quantification

• Both Figures 3 and 4 could be condensed or moved to supplemental

Reviewer #2 (Recommendations for the authors):

The following points are suggestions to improve the overall presentation and impact of the manuscript.

1. In the first section of the results the authors mention assessing the efficiency of Cre-mediated recombination in the PDGFRa-TDP43 mice by measuring EGFP expression in NG2-positive OPCs. It is likely that a sentence got deleted that described PDGFRa-CreER mice mated to EGFP Cre reporter (RCE) mice to allow for this assessment. It is mentioned in the figure 1 legend.

2. The data presented clearly shows that TDP-43 is required for the survival of OPCs in young and older adult animals. Strikingly, the authors also show that the population of OPCs is quickly restored following their loss. The authors make the reasonable suggestion that the repopulated cells are derived from the minor population of OPCs that did not originally delete TDP-43. Nevertheless, it also seems possible that these cells are derived from a "pre-OPC" progenitor pool that through cell division and maturation are able to replenish the depleted OPC pool. The authors' interpretation is based on their extensive, groundbreaking work on how OPCs replenish lost oligodendrocytes, but it might be possible that distinct mechanisms respond to OPC loss. It might be worth mentioning this alternative possibility in the discussion.

3. The authors have done an excellent job demonstrating recombination efficiency and specificity using the PDGFRa and Mobp Cre drivers. Nevertheless, they have not shown similar data for the Mog Cre driver. This data would be helpful when considering the apparent lack of impact on oligodendrocyte viability, in contrast with the other drivers, in the Mog-Cre mice.

4. The sentence starting the new section on page 8 begins "Despite the eventual vulnerability of oligodendrocytes to loss of TDP-43, in both Mobp-TDP43 KO and Mog-197 TDP43 KO mice", which is confusing. The authors have clearly shown oligodendrocyte "vulnerability" in the Mobp animals, but up to this point in the manuscript all of the assays presented appear to show unperturbed oligodendrocytes in the Mog animals. Subsequently they demonstrate thinner myelin in these mice, but the introductory statement should be clarified or re-written.

5. Chang et al. (2021) recently demonstrated that the loss of TDP-43 in myelinating Schwann cells resulted in aberrant splicing of the paranodal component Neurofascin, which is also expressed by oligodendrocytes. The authors of the current study also demonstrate aberrant splicing in the TDP-43 deficient oligodendrocytes. It would be interesting to know whether Neurofascin RNA is also abnormally processed in the oligodendrocyte mutants. Paranodal abnormalities might contribute to the clinical phenotype of the mutant animals.

Reviewer #3 (Recommendations for the authors):

Using their mouse models, the authors are able to show the role of TDP-43 in OPC survival, and the role of TDP-43 in early and late stages of postmitotic oligodendrocytes. It would be useful to have a summary figure that shows the role of TDP-43 in OPC/oligodendrocyte development.

In lines 164-66, the authors mention that their results are "similar to the phenotype exhibited by Cnp-Cre;Tardbp 165 fl/fl mice (J. Wang et al. 2018), in which recombination occurs in OPCs, early postmitotic oligodendrocytes, and Schwann cells in the PNS (Lappe-Siefke et al. 2003)." This statement and citations are confusing. In J. Wang et al., 2018 they confirmed that Cre-mediated recombination occurs for over 95% of mature oligodendrocytes, which are labeled with APC-CC1 and they saw no colocalization of GFP with NG2-positive OPCs, thus suggesting that Cnp-Cre-mediated recombination in the spinal cord is restricted to mature oligodendrocytes. In addition, Lappe-Siefke et al. 2003 does not look at Schwann cells in the PNS. Please clarify these citations.

Lines 343-4. The sentence "Thus, death of only a few proliferating OPCs upon removal of TDP-43 is likely to induce a cascading depletion, capturing neighboring cells (also TDP-43 deficient) as they are induced to proliferate" is confusing. Can the authors clarify what they mean by a cascading-depletion of TDP-43 in other neighboring cells?

The methods are easy to follow, however for the RNA isolation section (line 569), it would be helpful to include the number of oligodendrocytes that were sorted and used for RNA extraction.

eLife. 2022 Mar 21;11:e75230. doi: 10.7554/eLife.75230.sa2

Author response


Essential revisions:

The majority of the comments are focused on the clarity of the written document, as well as suggestions for making the figures more informative as well as specific recommendations for increasing the clarity of the figures and providing quantification of a few of the figures.

– There were a few additional experimental data requested centered on reporter data on recombination efficiency (see reviewer 2 point #3)- and neurofascin splicing ( see rev 2 point 5).

The efficiency of Cre recombination in Mog-iCre mice was quantified by crossing these mice to a Cre-dependent EGFP reporter mouse line (“RCE”). Analysis of these mice [add experimental details – timing of tam and sac], revealed that 97.3±0.7% of ASPA+ oligodendrocytes were EGFP+ in the cerebral cortex ( = recombination efficiency), whereas 95.9±0.5% of EGFP+ cells were ASPA+ ( = recombination specificity). A small percentage of neurons exhibit Cre activity in this animals (P90: 3.2±0.3%, P180: 4.9±0.7%). These data have been added as new Figure 2—figure supplement 1.

We did not observe any changes in Nfasc splicing in cortical oligodendrocytes with Tardbp deletion. These data are consistent with observations recently reported by Chang et al. (2021), in which Nfasc missplicing was observed in sciatic nerve, but not in the spinal cord after Cnp-Cre-mediated deletion of Tardbp (see Figure 6C of Chang et al. 2021). These observations have been added to the Discussion section of the manuscript (p. 18).

– Please provide more details and quantification of the immunohistochemistry images shown as noted by reviewer 1 in legends and methods (in particular Figures 4, 5).

We have added quantification of the prevalence (# of events/µm3) of abnormal association of TDP-43 KO oligodendrocytes with non-axonal structures in Figure 4—figure supplement 4. The method of quantification is now described in the Figure 4—figure supplement 4 legend and the Materials and Methods section.

– Please address reviewer 3 comment regarding potential loss of OPC identity. All reviewers agreed this is important especially since one marker (NG2) was used to define OPCs. Because the absence of TDP-43 alters splicing, it is possible that NG2 is not being expressed. This could also help explain the lack of astrogliosis.

We agree this is an important issue. In these experiments, a Cre-dependent EGFP reporter transgene (RCE) was included to follow the fate of Cre-recombined OPCs over time. Immunolabeling for EGFP in these mice revealed that all EGFP+ TDP-43 KO OPCs disappear, rather than downregulate NG2. We also show that PDGFRα+ cells also disappear upon Cre recombination. These data have been added to Figure 1—figure supplement 1D. Of note, a previous study that used diphtheria toxin to ablate OPCs reported that widespread apoptosis of OPCs does not induce microglial activation or pro-inflammatory changes (Birey et al., 2015).

Reviewer #1 (Recommendations for the authors):

Major Strengths:

• Mog-TDP43 and Mobp-TDP43 KO mice represent useful tools for the field to study early and late stages of oligodendrocyte maturation

• The stage-dependent role of TDP-43 in oligodendrocyte maturation, morphology, and function is particularly novel.

• Transcriptomic analysis (Figure 6) is particularly strong, showing that TDP-43 KO oligodendrocytes exhibit missplicing of cytoskeletal-associated genes

Major Weaknesses:

• Very minimal quantification of immunohistochemistry images (Figure 4 in particular). Quantification of all images must be included with details in methods/legends

Quantification of abnormal association with non-axonal structures has been quantified (Figure 4—figure supplement 4). The methods of quantification have been added to the Material and Methods section.

• Several figures could be split up into separate figures to enhance clarity. Schematics should also be included in separate figures to provide additional visuals of experiments

Figure 3 and 4 have been split and a summary figure has been generated (Figure 6—figure supplement 5) outlining the distinct role of TDP-43 at different stages of oligodendrocyte development.

• No stain of TDP-43 in immunohistochemistry images. Please address.

In the mouse brain, TDP-43 protein is most highly expressed by neurons. With available antibodies, immunostaining for TDP-43 only resulted in labeling of neuronal somata. Although TDP-43 is below the limit of detection within oligodendrocyte lineage cells in tissue sections, mRNA for TDP-43 is consistently detected using RNA sequencing approaches and the profound phenotypes we observe indicate its importance in promoting the survival of OPCs, oligodendrocyte maturation, and oligodendrocyte stability.

• No quantification of behavior/hindlimb weakness (Figure 5)

Given the similarity of the motor abnormalities (limp tail, hindlimb weakness) exhibited by TDP43 cKO mice to that observed in mice subjected to experimental autoimmune encephalomyelitis (EAE), we used the well-established EAE 0-5 severity scoring scale to quantify the behavior of these mice. These data are now included in Figure 5E.

• Narrative is lost through the vast amount of data shown, especially within each figure

• Figure 3 axon thinning and density could be shown via A,B,D,E,F and without C and G

• Figure 4 does not need examples of abnormal structures (could be put in supplement), and lacks quantification

• Both Figures 3 and 4 could be condensed or moved to supplemental

We have now separated the main figures (Figures 3 and 4) and moved the data indicated into Supplementary Data.

Reviewer #2 (Recommendations for the authors):

The following points are suggestions to improve the overall presentation and impact of the manuscript.

1. In the first section of the results the authors mention assessing the efficiency of Cre-mediated recombination in the PDGFRa-TDP43 mice by measuring EGFP expression in NG2-positive OPCs. It is likely that a sentence got deleted that described PDGFRa-CreER mice mated to EGFP Cre reporter (RCE) mice to allow for this assessment. It is mentioned in the figure 1 legend.

Indeed, all of the mice used in this study expressed a Cre-dependent EGFP reporter (RCE) to assess Cre recombination efficiency and to allow visualization of the morphology of TDP-43 KO cells. This information is now included in the Results (p.5).

2. The data presented clearly shows that TDP-43 is required for the survival of OPCs in young and older adult animals. Strikingly, the authors also show that the population of OPCs is quickly restored following their loss. The authors make the reasonable suggestion that the repopulated cells are derived from the minor population of OPCs that did not originally delete TDP-43. Nevertheless, it also seems possible that these cells are derived from a "pre-OPC" progenitor pool that through cell division and maturation are able to replenish the depleted OPC pool. The authors' interpretation is based on their extensive, groundbreaking work on how OPCs replenish lost oligodendrocytes, but it might be possible that distinct mechanisms respond to OPC loss. It might be worth mentioning this alternative possibility in the discussion.

Thank you for this suggestion. Although we favor the conclusion that repopulation occurs primarily from surviving cells, based on the recombination efficiency and qualitative assessments of proliferation of glial progenitors around the lateral ventricles, we now note this possibility in the Discussion (p. 14).

3. The authors have done an excellent job demonstrating recombination efficiency and specificity using the PDGFRa and Mobp Cre drivers. Nevertheless, they have not shown similar data for the Mog Cre driver. This data would be helpful when considering the apparent lack of impact on oligodendrocyte viability, in contrast with the other drivers, in the Mog-Cre mice.

We now provide these data in Figure 2—figure supplement 1.

4. The sentence starting the new section on page 8 begins "Despite the eventual vulnerability of oligodendrocytes to loss of TDP-43, in both Mobp-TDP43 KO and Mog-197 TDP43 KO mice", which is confusing. The authors have clearly shown oligodendrocyte "vulnerability" in the Mobp animals, but up to this point in the manuscript all of the assays presented appear to show unperturbed oligodendrocytes in the Mog animals. Subsequently they demonstrate thinner myelin in these mice, but the introductory statement should be clarified or re-written.

We have removed the text referring to the vulnerability and modified the introductory statement to the following: In both Mobp-TDP43 KO and Mog-TDP43 KO mice, oligodendrocytes were able to mature and form myelin sheaths, global myelin tracts within the brain were established (Figure 3—figure supplement 1A), and there was no evidence of astrogliosis early in development (P30) (Figure 3—figure supplement 2).

5. Chang et al. (2021) recently demonstrated that the loss of TDP-43 in myelinating Schwann cells resulted in aberrant splicing of the paranodal component Neurofascin, which is also expressed by oligodendrocytes. The authors of the current study also demonstrate aberrant splicing in the TDP-43 deficient oligodendrocytes. It would be interesting to know whether Neurofascin RNA is also abnormally processed in the oligodendrocyte mutants. Paranodal abnormalities might contribute to the clinical phenotype of the mutant animals.

We examined our RNAseq datasets and did not observe that Nfasc was aberrantly spiced after deletion of Tardbp. Of note, Chang et al. (2021) observed that aberrant splicing of Nfasc occurred in the sciatic nerve but not in the spinal cord in Cnp-Cre cKO mice, which recombine in both the CNS and PNS. This result is now reported in the Discussion (p. 18).

Reviewer #3 (Recommendations for the authors):

Using their mouse models, the authors are able to show the role of TDP-43 in OPC survival, and the role of TDP-43 in early and late stages of postmitotic oligodendrocytes. It would be useful to have a summary figure that shows the role of TDP-43 in OPC/oligodendrocyte development.

We have added a new summary figure to accompany the manuscript (Figure 6—figure supplement 5).

In lines 164-66, the authors mention that their results are "similar to the phenotype exhibited by Cnp-Cre;Tardbp 165 fl/fl mice (J. Wang et al. 2018), in which recombination occurs in OPCs, early postmitotic oligodendrocytes, and Schwann cells in the PNS (Lappe-Siefke et al. 2003)." This statement and citations are confusing. In J. Wang et al., 2018 they confirmed that Cre-mediated recombination occurs for over 95% of mature oligodendrocytes, which are labeled with APC-CC1 and they saw no colocalization of GFP with NG2-positive OPCs, thus suggesting that Cnp-Cre-mediated recombination in the spinal cord is restricted to mature oligodendrocytes. In addition, Lappe-Siefke et al. 2003 does not look at Schwann cells in the PNS. Please clarify these citations.

We have revised the reference to the following prior studies: Chang et al. 2021 and Tognatta et al. 2017 (p. 7).

Lines 343-4. The sentence "Thus, death of only a few proliferating OPCs upon removal of TDP-43 is likely to induce a cascading depletion, capturing neighboring cells (also TDP-43 deficient) as they are induced to proliferate" is confusing. Can the authors clarify what they mean by a cascading-depletion of TDP-43 in other neighboring cells?

We have clarified this statement (Discussion, p. 14).

The methods are easy to follow, however for the RNA isolation section (line 569), it would be helpful to include the number of oligodendrocytes that were sorted and used for RNA extraction.

This method has been clarified.

References

Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, Baralle FE (2011) TDP-43 regulates its mRNA levels through a negative feedback loop. Embo J 30:277–288.

Birey, F., Kloc, M., Chavali, M., Hussein, I., Wilson, M., Christoffel, D. J., Chen, T., Frohman, M. A., Robinson, J. K., Russo, S. J., Maffei, A., and Aguirre, A. (2015). Genetic and Stress-Induced Loss of NG2 Glia Triggers Emergence of Depressive-like Behaviors through Reduced Secretion of FGF2. Neuron, 88(5), 941–956. https://doi.org/10.1016/j.neuron.2015.10.046.

Chang, Kae Jiun, Ira Agrawal, Anna Vainshtein, Wan Yun Ho, Wendy Xin, Greg Tucker-Kellogg, Keiichiro Susuki, Elior Peles, Shuo Chien Ling, and Jonah R. Chan. 2021. “TDP-43 Maximizes Nerve Conduction Velocity by Repressing a Cryptic Exon for Paranodal Junction Assembly in Schwann Cells.” eLife 10 (March). https://doi.org/10.7554/elife.64456.

Hughes, Ethan G., Shin H. Kang, Masahiro Fukaya, and Dwight E. Bergles. 2013. “Oligodendrocyte Progenitors Balance Growth with Self-Repulsion to Achieve Homeostasis in the Adult Brain.” Nature Neuroscience 16 (6): 668–76. https://doi.org/10.1038/nn.3390.

Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, Lee VM (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 121:726–738.

Orthmann-Murphy, Jennifer, Cody L Call, Gian Carlo Molina-Castro, Yu Chen Hsieh, Matthew N Rasband, Peter A Calabresi, and Dwight E Bergles. 2020. “Remyelination Alters the Pattern of Myelin in the Cerebral Cortex.” eLife 9: 1–61. https://doi.org/10.7554/eLife.56621.

Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14:459–468.

Tognatta, R., Sun, W., Goebbels, S., Nave, K. A., Nishiyama, A., Schoch, S., Dimou, L., and Dietrich, D. 2017. "Transient Cnp expression by early progenitors causes Cre-Lox-based reporter lines to map profoundly different fates". Glia 65(2), 342–359. https://doi.org/10.1002/glia.23095.

Traka, M., Podojil, J. R., McCarthy, D. P., Miller, S. D., and Popko, B. (2016). Oligodendrocyte death results in immune-mediated CNS demyelination. Nature Neuroscience, 19(1), 65–74. https://doi.org/10.1038/nn.4193.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Heo D, Ling JP, Molina-Castro GC, Langseth AJ, Waisman A, Nave K-A, Möbius W, Wong PC, Bergles DE. 2021. Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43. NCBI Gene Expression Omnibus. GSE188903 [DOI] [PMC free article] [PubMed]
    2. Hrvatin S, Hochbaum DR, Nagy MA, Cicconet M, Robertson K, Cheadle L, Zilionis R, Ratner A, Borges-Monroy R, Klein AM, Sabatini BL, Greenberg ME. 2018. Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. NCBI- GSE102827. [DOI] [PMC free article] [PubMed]
    3. Marques S, Zeisel A, Codeluppi S, van Bruggen D, Falcao AM, Xiao L, Li H, Haring M, Hochgerner H, Romanov RA, Gyllborg D, Manchado AM, Manno GL, Lonnerberg P, Floriddia EM, Rezayee F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G. 2016. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. NCBI Gene Expression Omnibus. GSE75330 [DOI] [PMC free article] [PubMed]

    Supplementary Materials

    Figure 6—source data 1. Raw, cropped, and annotated images of the western blot of mouse-Ermin (red; IRDye 680RD) and rabbit-GAPDH (green; IRDye 800CW).

    The molecular weight of Ermin is 42 kDa and of GAPDH is 37 kDa.

    Supplementary file 1. Differential gene expression of TDP-43 KO oligodendrocytes.

    Excel file of bulk RNA-Seq that includes average FPKM of each gene, log fold change (FC), p value, and false discovery rate (FDR) for the following comparisons: (1) Mog-TDP43-WT vs. Mobp-TDP43-WT, (2) Mog-TDP43-KO vs. Mobp-TDP43-KO, (3). Mog-TDP43-KO vs. Mog-TDP43-WT, (4) Mobp-TDP43-KO vs. Mobp-TDP43-WT, and (5) TDP43-WT vs. TDP43-KO.

    elife-75230-supp1.xlsx (3.3MB, xlsx)
    Transparent reporting form

    Data Availability Statement

    Bulk RNA-seq data of P30 FACS-isolated oligodendrocytes from Mobp-TDP43 and Mog-TDP43 mouse lines has been deposited to GEO (GSE188903). Processed data, including the raw count number, normalized counts, and FPKM values, are provided as Supplementary Data (Supplementary file 1. Differential gene expression of TDP-43 KO oligodendrocytes).

    The following dataset was generated:

    Heo D, Ling JP, Molina-Castro GC, Langseth AJ, Waisman A, Nave K-A, Möbius W, Wong PC, Bergles DE. 2021. Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43. NCBI Gene Expression Omnibus. GSE188903

    The following previously published datasets were used:

    Hrvatin S, Hochbaum DR, Nagy MA, Cicconet M, Robertson K, Cheadle L, Zilionis R, Ratner A, Borges-Monroy R, Klein AM, Sabatini BL, Greenberg ME. 2018. Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. NCBI- GSE102827.

    Marques S, Zeisel A, Codeluppi S, van Bruggen D, Falcao AM, Xiao L, Li H, Haring M, Hochgerner H, Romanov RA, Gyllborg D, Manchado AM, Manno GL, Lonnerberg P, Floriddia EM, Rezayee F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G. 2016. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. NCBI Gene Expression Omnibus. GSE75330


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES